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Structured Abstract: (198/200) 
Aims 
To critically appraise, compare and synthesise the quality and acceptability of multi-item PROMs for 
adults with chronic or episodic headache. 
Methods 
Systematic literature searches of major databases (1980-2016) to identify published evidence of 
PROM measurement and practical properties. Data on study quality (COSMIN), measurement and 
practical properties per measure was extracted and assessed against accepted standards to inform 
an evidence synthesis. 
Results 
From 10,903 reviewed abstracts, 103 articles were assessed in full; 46 provided evidence for 23 
PROMs: eleven specific to the health-related impact of migraine (n=5) or headache (n=6); six 
assessed migraine-specific treatment response/satisfaction; six were generic measures.  
Evidence for measurement validity and score interpretation was strongest for two measures of 
impact - Migraine-Specific Quality of Life Questionnaire (MSQ v2.1) and Headache Impact Test 6-
item (HIT-6), and one of treatment response - the Patient Perception of Migraine Questionnaire 
(PPMQ-R). Evidence of reliability was limited, but acceptable for the HIT-6. Responsiveness was 
rarely evaluated. Evidence for the remaining measures was limited. Patient involvement was limited 
and poorly reported.  
Conclusion 
Whilst evidence is limited, three measures have acceptable evidence of reliability and validity - HIT-
6, MSQ v2.1 and PPMQ-R. Only the HIT-6 has acceptable evidence supporting its completion by all 
‘headache’ populations.  
 
Key words:  
headache; patient-reported outcome; validity; reliability; systematic review 
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Background: (313) 
Headache disorders are common in the adult population; the most common - tension-type and 
migraine - have a one-year prevalence of 40% and 11% respectively [1,2,3]. Between 2-4% of the 
general population experience chronic headache [4,5]. Headache disorders can profoundly impact 
an individual’s functional ability and quality of life [3,6]. Affecting primarily young adults, the 
personal and economic burden of headache is substantial and comparable to other chronic 
conditions such as congestive heart failure, hypertension, or diabetes [7]. 
An individual’s self-report of the presence, severity, frequency and impact of headache is crucial to 
understanding the effectiveness of therapeutic interventions. Patient-reported outcome measures 
(PROMs), which seek to provide a patient-based assessment of the impact of headache on how 
people feel, function and live their lives are now available. Where recommendations to include 
PROMs in headache clinical trials are available [8,9], specific guidance for PROM-based outcome 
reporting does not exist. The integrity of PROM-based reporting is underpinned by clear evidence of 
essential measurement and practical properties in the clinical population of interest [10,11]. It 
cannot be assumed that the reliability and validity of measure is consistent across different types of 
headache, and evidence of PROM performance across different sub-types is often not available [12]. 
PROM score interpretation also requires guidance for what change in score reflects a meaningful 
change in ‘headache’ for the individual patient (minimal important change (MIC)) and what 
difference reflects a meaningful difference between groups of patients defined by some external 
anchor (minimal important difference (MID)) [10,11]. Structured reviews of PROM performance 
provide essential evidence to inform the selection of robust, relevant and acceptable measures.  
In this systematic review, we critically appraise, compare and synthesise published evidence of 
essential measurement and practical properties for clearly defined PROMs evaluated in adult 
headache populations. The review provides a transparent summary of the evidence-base with which 
to inform PROM selection for future application in headache-specific research. 
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Methods: (693)  
Identification of studies and PROMs: search strategy 
The search strategy was developed by experienced reviewers (KH, TM, RP, SP) and with expert 
librarian support to retrieve references relating to the development and/or evaluation of multi-item 
PROMs used in the assessment of adults (aged 18 years and above) with chronic or episodic 
headache including migraine.  
Medical subject headings (MeSH terms) and free text searching were used to reflect three 
characteristics: 1) population – headache and migraine; 2) type of assessment – patient-reported 
outcome measures (PROMs); and 3) measurement and practical properties [11,13,14]. The full 
search strategy is available in Appendix 1.1. 
Two databases were searched (MEDLINE (OVID), EMBASE (OVID); 1980 to December 2016) (figure 
1). A subsequent search incorporated the names of more than 50 multi- and single-item measures 
identified during the initial search (Appendix 1.2 and 1.3). From a total of 39 multi-item PROMs thus 
identified, 16 had been superseded by revised measures or were no-longer in use as evidenced by 
their lack of inclusion in studies published post 2000 (Appendix 2). Given that such measures are 
unlikely to be of interest, the eligibility criteria for the review and analysis was revised to focus on 
PROMs ‘in use’ post-2000.   
The citation lists of included articles and existing reviews were also reviewed [15,16]. Named author 
searches were conducted. Inclusion/exclusion criteria 
Titles and abstracts of all articles were independently assessed for inclusion/exclusion by two 
reviewers (TM, KH) and agreement checked. Published articles were included if they provided 
evidence of development/evaluation for clearly defined, reproducible, multi-item PROMs, following 
self-completion by adults who self-reported or had been diagnosed by a clinician as having a 
headache disorder. Articles relating solely to the application of measures without some evidence of 
measurement and/or practical properties were excluded. Articles describing the translation of 
PROMs and/or evaluations in non-English speaking populations were also excluded. Conference 
papers and abstracts were excluded.  
Included PROMs must be ‘in-use’ in research published between 2000-2016. PROMs were 
categorised as: generic (profile; utility) or condition-specific (headache; migraine). Clinician-
reported, diagnostic and screening measures were excluded. Domain-specific measures that were 
not specific to the impact of headache, and measures that were not clearly reproducible were 
excluded.  
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Data extraction and appraisal 
A data extraction form was informed by guidance for PROM evaluation [10,11,17], published PROM 
reviews [14,18,19] and the COnsensus-based Standards for the selection of health Measurement 
Instruments (COSMIN) checklist [20,21]. The form captured both study and PROM-specific 
information. Population diagnosis and diagnostic criteria (if any) were extracted. We sought 
evidence on: reliability (internal consistency; test–retest, intra/inter-tester); validity (content; 
construct; known groups); responsiveness; interpretation (minimal important change (MIC) and/or 
difference (MID)); and precision (data quality; end effects). Evidence for the practical properties 
included acceptability (relevance; respondent burden) and feasibility. Evidence of active patient 
involvement in PROM evaluation was also sought [18,22,23]. All publications were double-assessed 
(KH,TM) and agreement checked.  
Assessment of study methodological quality 
One experienced reviewer (KH) applied the COSMIN checklist to assess the methodological quality of 
included studies [20,21]. Methodological quality was evaluated per measurement property on a 4-
point rating scale (excellent, good, fair, poor) and determined by the lowest rating of any items in 
each checklist section [21]. 
Assessment of PROM quality 
A similar checklist for PROM quality does not exist. Therefore, a pragmatic checklist informed by a 
synthesis of various recommendations was adopted [18,19,21,24](Appendix 3: Table 2). To provide a 
global overview of the concepts captured within the reviewed headache-specific measures, items 
were categorized per domains of one of the most frequently used conceptual models of health-
related quality of life (HRQOL) – the Ferrans revision to the Wilson and Cleary model [25,26].  
Data synthesis  
A qualitative synthesis of evidence per reviewed PROM per reported measurement property 
informed the overall judgement of quality and acceptability. The synthesis combined four factors: 1) 
study methodological quality (COSMIN scores); 2) number of studies reporting evidence per PROM; 
3) results per measurement property (Appendix 3: Table 2); and 4) evidence of consistency between 
evaluations [23,27]. Two elements of the data synthesis are described: First, the overall quality of a 
measurement property was reported as: adequate (+), conflicting (+/-), inadequate (-), or 
indeterminate (?). Second, evidence for the overall quality of evidence was categorized: ‘strong’, 
‘moderate’, ‘limited’, ‘conflicting’, or ‘unknown’ [27]. 
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Results: (1874) 
Identification of studies and PROMs 
Study and PROM identification is summarized per PRISMA guidance in figure 1 (www.prisma-
statement.org). Forty-six articles provided evaluative evidence for 23 PROMs (Appendices 4 and 5 
(Tables 3 and 4)). Six assessed impact of headaches overall the EUROLIGHT [28]; Headache Activities 
of Daily Living Index (HADLI) [29]; Headache-specific Disability Questionnaire (HDQ) [30]; the 
Headache Impact Test (HIT) [3] and its short-form HIT-6 [31]; and a headache-specific modification 
of the Short-Form 36-item Health Survey [32]. Five were specific to the impact of migraine: 
Functional Assessment in Migraine questionnaire (FAIM) [33]; Headache Needs Assessment Survey 
(HANA) [34]; MIgraine Disability ASessment (MIDAS) [35]; Migraine-Specific Quality of Life 
Questionnaire (MSQ v2.1) [36]; and the Migraine-Specific Quality of Life (MSQOL) measure [37]. Six 
assessed response to and/or satisfaction with migraine-specific drug treatment: Completeness of 
Response to migraine therapy (CORS)[38]; Migraine Assessment of Current Therapy (Migraine-ACT) 
[39]; Migraine-Treatment Assessment Questionnaire (M-TAQ) [40]; Migraine-Treatment 
Optimisation Questionnaire (M-TOQ) [41]; Migraine Treatment Satisfaction Measure (MTSM)[42]; 
and the Patient Perception of Migraine Questionnaire – Revised (PPMQ-R) [43]. Item content of all 
specific measures is illustrated in Appendix 6 (Table 5). 
Finally, six generic measures had been assessed in headache populations: the Short-Form 36-item 
Health Survey (SF-36)[44], SF-12 [45], SF-8 [46], EuroQoL EQ-5D 3L [47], Health Utility Index-3 (HUI-
3)[48] and the Quality of Well-being Scale (QWB)[49,50]. 
Patient and study characteristics (Appendix 5 (Table 4)) 
Patient populations ranged 18 to 83 years, were largely white, often with large proportions of 
female participants. Sample sizes ranged 25 to more than 8,500. Populations included mixed, 
chronic and/or episodic headache or migraine. Where clinician-based diagnosis was described, most 
adopted the International Classification of Headache Disorders (ICHD-II). However, for many, 
patients were self-diagnosed, and a wide range of diagnostic criteria were described. Most studies 
were cross-sectional or longitudinal surveys. Nine were clinical trials or involving data secondary 
analysis. Fourteen studies were specific to PROM development and/or initial evaluations. Most 
evaluations were with US populations. 
Measurement properties and methodological quality 
Study methodological quality per measurement property per reviewed PROM is presented in 
Appendix 7 (Table 6). The overall evidence synthesis is presented in Table 1. 
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i. PROMs assessing Migraine and Headache-specific impact (n=11) 
Apart from the FAIM, MSQ v2.1, MSQoL and HIT, all measures lack a clear description of aim, the 
concepts being measured or the process of items generation. The FAIM [33], MSQ v2.1 [36] and 
MSQoL [37] involved expert clinicians and patients in item generation, supporting a positive rating of 
content validity.  
The HIT ‘item bank’ was informed by four legacy measures – the MIDAS, MSQ (v1.0), Headache 
Disability Index (HDI) and Headache Impact Questionnaire (HIMQ) – and consultation with clinicians 
[3]. Apart from the MSQ, item generation for these measures is poorly reported but largely driven by 
clinical opinion. Additional evaluations of the content validity of the item bank or short form 
measures is not described. Clinical opinion, literature review, and/or the completion of established 
questionnaires were the main sources of items for the remaining measures. There was no evidence 
of active patient collaboration in PROM development and/or evaluation.  
The shortest measures are the MIDAS (5-items) and HIT-6 (6 items); the longest is the 103-item 
EUROLIGHT (Table 2). Apart from the FAIM, all assess headache/migraine symptomology. While five 
headache-specific measures assess pain, the migraine-specific measures do not. Only the HANA, 
MSQv2.1 and HIT-6 assess fatigue.  
All assess the impact of headache/migraine on social function, activities of daily living and/or work. 
Seven – FAIM, HANA, MSQv2.1, MSQOL, HIT, HIT-6, EUROLIGHT – assess the emotional burden of 
headache/migraine; five of these – FAIM, MSQv2.1, HIT, HIT-6, EUROLIGHT – plus the HADLI, assess 
the impact on cognition and difficulty thinking.  
Acceptable evidence of measurement dimensionality from studies of at least moderate 
methodological quality was reviewed for five measures – FAIM [33], MSQv2.1 [12,51], MSQoL [52], 
HIT [3], HIT-6 [53]; three have moderate to strong evidence of both structural validity and internal 
consistency – FAIM [33], MSQ v2.1 [12,36,51,54] and the HIT-6 [31,41,53,55,56] (Table 1; Appendix 
7). Three measures have acceptable evidence of internal consistency reliability from studies of at 
least moderate methodological quality, supporting application in the assessment of groups 
(FAIM)[33] and individuals (MSQ v2.1 [12,36,51], HIT-6 [53,56]) (Table 1; Appendix 7); but for the 
majority evidence was limited (n=3), from poor quality studies (n=3) or not available (n=1). Only the 
HIT [31,57] and HIT-6 [31,53,56,57] have acceptable evidence of temporal stability supporting 
application in the assessment of groups and individuals. Evidence for the remaining measures was 
limited.  
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Five measures have acceptable evidence from good quality studies describing their construct validity 
– FAIM [33], MIDAS [56], MSQ v2.1 [12,36,43,53], HIT [57] and HIT-6 [12,53,56,57]. For the 
remaining measures evidence was of poor quality (n=4) or not available (n=2); authors often failed 
to hypothesise a priori the association between variables.  
Evidence of responsiveness was limited. Statistically significant between-group differences for 
average HIT-6 and total HIT change scores were reported for patients categorised per self-reported 
change (better / same / worse) in physical activity, level of frustration or daily activities following a 
3-month follow-up period of ‘usual care’ [31].  
Large and moderate effect size statistics were reported for the MSQv2.1 [12] and HIT-6 [53] in 
patients who reported large or moderate improvement in the number of headache days following a 
pharmaceutical-based clinical trial, respectively. Following a non-comparative, observational study 
of zolmitriptan for an acute migraine attack, small and moderate ES statistics were reported for the 
SF-36 and MSQoL respectively [52].  
Following completion of the HIT-6 by patients with chronic daily headache in a trial of usual medical 
care (UMC) versus UMC plus acupuncture, an anchor-based estimate of the MIC was calculated as 
approximately 3.7; the MID was estimated as 2.3 [58]. Change in HIT-6 scores that exceeded the 
proposed MIC were reported in patients with chronic migraine receiving onabotulinumtoxinA in a 
placebo-controlled double blind trial; a between group difference that exceeded the MID, in favour 
of the active treatment, was also reported [59].  
Both anchor-based [60,61] and distribution-based estimates [60] were calculated for the MSQv2.1 
following completion by patients with chronic migraine. Cole et al [60] proposed an MIC of 5.0 for 
the RR domain, with ranges for the RP (5.0 to 7.9) and EF (range 8.0 to 10.6) domains; MIDs were 
recommended as: RR 3.2, RP 4.6, EF 7.5 [60]. A between group difference that exceeded the 
proposed MID, in favour of the active treatment, was reported for the MSQv2.1 RR domain only in 
patients with chronic migraine receiving onabotulinumtoxinA in a placebo-controlled double blind 
trial [59]. However, within-individual change scores were larger than the proposed MIC for each 
domain for patients receiving active treatment. 
 
ii. PROMs assessing response to or satisfaction with migraine-specific treatment (n= 6 
measures) 
Four of the six measures - the CORS, M-TOQ, MTSM and PPMQ-R - have acceptable descriptions of 
the measurement aim, conceptual underpinning and item generation. Although detail is limited, 
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three measures – CORS, MTSM and PPMQ-R - involved both expert clinicians and patients in item 
generation (the MTSM involved US and UK participants), supporting a positive rating of content 
validity; the M-TAQ utilised patient interviews and focus-groups, with additional reference to 
established treatment-optimisation measures.  
Item generation for the M-ACT [39] and the M-TOQ [41] was informed by clinical evidence and the 
consensus of clinical headache experts and researchers; patients were not involved, supporting a 
negative rating of content validity. There was no evidence of active patient collaboration.  
The shortest measures are the M-ACT (4-items) and M-TOQ-5 (5-items); the longest is the 45-item 
MTSM (Appendix 4). Apart from the M-ACT and M-TAQ, all assess migraine symptomology, including 
pain severity, and the wider impact on activities of daily living and/or work; the PPMQ-R also 
assesses limitations in social functions (Appendix 6). The CORS, M-TOQ-15 and PPMQ-R assess the 
emotional burden of migraine; just the CORS and PPMQ-R also assess cognition and difficulty 
thinking. Three measures assess if the patient has ‘returned to normal’ - CORS, M-ACT, M-TOQ. All 
assess confidence in/or satisfaction with treatment; the M-TOQ assesses treatment side-effects.  
Only the PPMQ-R has acceptable evidence of measurement dimensionality and internal consistency 
reliability from studies of at least moderate methodological quality (Table 1; Appendix 7). For three 
measures – CORS, M-TOQ, MTSM - evidence was acceptable but limited.  
Only the M-ACT has acceptable evidence of temporal stability from several studies of fair 
methodological quality, supporting application in the assessment of groups (Table 1; Appendix 7). 
Evidence for three measures - M-TAQ, M-TOQ, PPMQ-R - was limited to single studies judged to be 
of fair quality (Table 1; Appendix 7). Only the PPMQ-R and MTSM have acceptable evidence of 
construct validity from good quality studies. For the remaining measures evidence was limited 
(CORS, M-TAQ, M-TOQ) or from poor quality (M-ACT) studies.  
Following a 2-month pharmaceutical trial, small to moderate change score correlations between the 
CORS and the PPMQ-R supported a priori hypothesised associations, providing acceptable, but 
limited, evidence of responsiveness [38]. Further criterion-based evidence, comparing the 
comparative CORS with change in CORS sub-sets at 2-months, provided additional, hypothesis driven 
evidence of responsiveness [38]. Small to moderate effect size statistics were reported for the 
PPMQ-R in patients categorised per self-reported improvement (range 0.14 to 0.50) or worsening 
(range 0.06 to 0.23) in pain severity; the largest ES were reported for the Efficacy and Function 
domains [43]. 
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The Standard Error of Measurement (SEM) was calculated for the PPMQ-R, as a reflection of the 
within individual minimal change in score (MIC) [43]. Apart from the Cost domain (SEM 11.0), SEM 
estimates ranged 3.4 (Bothersome) to 5.4 (Total score), supporting an MIC recommendation of 5 
points for the total score and Efficacy, Function and East of Use domains. Results suggest that the 
Cost domain is highly variable and not responsive to change in migraine severity or role limitation.  
Estimates of the minimally important change and minimally important difference were reviewed for 
three headache-specific measures - MSQ v2.1 [36], HIT-6 [31], PPMQ-R [43]. Completion of the HIT-6 
by Dutch patients with chronic tension-type headache [62] and episodic migraine [63] suggested a 
wider range of MIC values –from -2.5 [63] to -8.0 [62] than that determined in a US population with 
chronic daily headache (-3.7) [58]. The differences were largely explained by use of different anchors 
– where a greater perceived change was the imposed anchor, a larger MIC was calculated. An MIC of 
>8.0 suggests that improvement must be present in at least two of the six HIT-6 items [62], which 
may be judged a relevant treatment effect [62,63]. Similarly, suggested MID values range from -1.5 
(episodic migraine) [63] to -2.3 (chronic daily headache) [58]. 
 
iii. Generic PROMs (n= 6) 
Evaluations of all generic measures in the headache population were very limited. There was no 
evidence exploring the content validity or relevance of the six reviewed generic measures with the 
headache population. There was no evidence of active patient collaboration. 
Where applicable, there was no evidence of measurement dimensionality or internal consistency 
reliability (Table 1). Just one measure – the QWB-SA - had conflicting evidence of temporal stability 
from one study, judged to be of poor methodological quality [64] (Table 1; Appendix 7).  
Acceptable evidence of construct validity from several studies judged to be of fair or good 
methodological quality, was reviewed for both the SF-36 [36,55,65] and the SF-8 [7,31,57,56]; for 
the SF-12 evidence was limited (Table 1; Appendix 7). For the remaining measures evidence was 
limited (EQ-5D) or of poor quality (HUI-3, QWB). There was no evidence of measurement 
responsiveness. 
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Discussion (1219) 
High quality, relevant and acceptable PROMs provide patient-derived evidence of the impact of 
headache and the relative benefit of associated healthcare at both the time of the headache and the 
intervening period. The importance of capturing the patient perspective is reflected in the large 
number of measures included in this review. However, apart from two condition-specific – HIT-6 and 
MSQv2.1 - and one treatment-response – PPMQ-R – measures for which strong evidence was 
reviewed, evidence was largely limited or not available.  
This is the first systematic review to include a methodological assessment of both study and PROM 
quality in the headache population. Clarity in PROM focus is an essential, but often over-looked 
aspect of PROM development [24,80]. Except for four condition-specific - MSQ v2.1, MSQoL, HIT, 
HIT-6 - and four treatment-response measures - CORS, M-TOQ, MTSM, PPMQ-R - all lacked a clear 
description of the measurement aim. Moreover, the condition-attribution of measures was not 
always self-evident: just three ‘migraine-specific’ measures assessed the impact of ‘migraine’ – 
FAIM, MSQ v2.1, MSQoL. The HANA includes both ‘migraine’ and ‘headache’ in the item stem and, 
despite the name, the MIDAS assesses the impact of ‘headache’. It is suggested that the attribution 
of ‘headache’ supports a ‘broader’ assessment than would be achieved with ‘migraine’; moreover, 
many patients may be unaware of a migraine diagnosis [3]. The HIT item content was informed by 
both migraine (MSQ and MIDAS) and headache-specific (HIMQ, HDI) measures; a content 
comparison failed to reveal any systematic differences in concept coverage and further evaluation in 
a mixed population supported the uni-dimensionality of headache disability [3]. Evidence further 
supports the ability of the HIT to assess headache disability across a wide spectrum of impact, 
avoiding the potential for ceiling effects, following completion by headache and migraine 
populations [3,63]. Just four measures - the HIT-6, HADLI, HDQ, MIDAS – have been evaluated in 
both headache and migraine populations. However, whilst evidence is strong for the HIT-6, the 
remaining measures should be applied with caution.  
Except for two condition-specific – MSQv2.1, MSQoL - and four treatment-response measures – 
CORS, M-TAQ, MTSM, PPMQ-R - the extent of patient participation was limited and poorly detailed. 
Moreover, except for three measures – MSQoL, PPMQ-R, EUROLIGHT - PROM relevance, content 
and face validity was not explicitly explored with patients and/or expert panels. Item content for the 
remaining measures was informed by a mix of qualitative research with clinicians, reference to 
existing measures, published literature and/or completed questionnaires. Successful treatment for 
headache disorders should seek to improve both overall quality of life, as well as an individual’s 
quality of life during the attack [37]; and assessment should seek to capture these distinctions. 
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Although varying in length, there was a similarity of item content across condition-specific measures. 
Most assessed headache/migraine-related symptomology; pain severity was commonly assessed by 
headache-specific and treatment-response measures, but not by the migraine-specific measures. 
Just two measures - MSQv2.1, HIT-6 – assessed fatigue. Measures with a primary focus on 
symptomology have been criticised for failing to take into consideration the longer-term 
consequence of, or fear associated with, a potentially severe headache or migraine, such as evading 
commitments or making plans [81,82]. Nevertheless, except for the FAIM and HANA, all condition-
specific and most treatment-response measures also assessed the wider impact of headache on 
social function and interactions, activities of daily living and/or work. Several measures - MSQv2.1, 
HIT, HIT-6, EUROLIGHT, CORS, PPMQ-R - also assessed both the emotional burden and cognitive 
impact of headache/migraine. 
Three condition-specific - FAIM, MSQv2.1, HIT-6 - and one treatment-response - PPMQ-R - measures 
have strong evidence of both structural validity and internal consistency reliability. Factor analysis 
supported the uni-dimensionality of the FAIM following completion by migraineurs, and the HIT-6 as 
a measure of ‘headache disability’ following completion by mixed populations. A three-domain 
structure of the MSQv2.1 was supported – Role Restriction (RR), Role Prevention (RP) and Emotional 
Function (EF) - following completion in both chronic and episodic migraine populations. However, for 
most measures evidence of structural validity or internal consistency reliability was limited, from 
methodologically poor quality studies or not available. Evidence of temporal stability was also 
limited, and available only for the HIT, HIT-6, M-ACT, M-TAQ, M-TOQ and PPMQ-R. There was no 
evaluation of measurement error.  
Five condition-specific (FAIM, MIDAS, MSQ v2.1, HIT, HIT-6), two treatment-response (MTSM, 
PPMQ-R) and two generic (SF-36, SF-8) measures have acceptable evidence of construct validity 
from good quality studies. For the remaining measures, evidence was limited, of poor 
methodological quality or not available. Methodological inadequacies included small sample sizes 
and a failure to hypothesise a priori the expected association between variables. As reported in 
other reviews [18,19], there was limited evidence of responsiveness: just two studies [31,38] 
provided acceptable, but limited, evidence for the CORS and HIT measures. Evaluative measures 
require evidence of responsiveness to demonstrate that they can detect real change in condition 
over time; without such evidence measures should be applied with caution. 
Whilst a limitation of the review is that we have only included evaluations in English, the context, 
setting and population are important in appraising evidence of PROM measurement and practical 
properties [83]. Moreover, the diversity of reviewed measures reflects the wide range of assessment 
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approaches in current use. Reviewed studies were of adults aged 18 years and over; with no upper 
age-limit imposed. All reviewed studies excluded people with significant co-morbidities. We are 
confident that the results are generalizable to the wider population of English-speaking adults with 
headache, but may not reflect the experience of adults with headache who have significant co-
morbidities or do not speak English. 
All data from included studies was double extracted and agreement checked (KH, TM). However, the 
COSMIN grading and synthesis score was applied by a single, experienced reviewer (KH). Although 
applied in several recent reviews [19,84], the grading system itself lacks robust evidence of reliability 
and validity and should therefore be interpreted with caution.  
The lack of reporting guidance and significant heterogeneity in outcome assessment detailed in this 
review, highlight the importance of establishing guidance on outcome reporting in this population. 
Future research should seek to establish international, multi-perspective guidance for a core set of 
outcomes to include in future headache research and across routine practice settings. The first step 
in this process is to seek consensus on which outcomes should be assessed, as a minimum, in future 
clinical trials or routine practice settings [85]. Informed by recommendations from this review, the 
second step is to determine the ‘best way’ to assess these core outcomes.  
Although many PROMs were reviewed following their evaluation in the headache and/or migraine 
population, study methodological quality was often poor and evidence of essential measurement 
properties largely unavailable or limited. Such limitations hinder PROM data interpretation from 
clinical trials, audit or quality assurance initiatives. However, three measures – HIT-6, MSQv2.1 and 
the PPMQ-R – had acceptable, and often strong, evidence of reliability and validity following 
completion by patients with headache (HIT-6) or migraine (HIT-6, MSQv2.1, PPMQ-R) and are 
recommended for consideration in future clinical research and routine practice settings as measures 
of headache-specific impact, migraine-specific impact, or migraine-treatment response respectively. 
However, the similarity of item content across all three measures suggests that a further exploration 
of the attribution, relevance and acceptability of the measures with representative members of the 
patient population is warranted. Further comparative evidence of widely used generic measures and 
evidence of measurement responsiveness of all measures is urgently required.  
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Article Highlights: 
 Despite the large number of reviewed PROMs currently used with patients with headache, 
most have not involved patients in the development process and may lack relevance to the 
patients experience of headache. Most also lack clarity with regards to measurement aim 
and have limited evidence of essential measurement properties, limiting confidence in data 
interpretation. These PROMs should be used and interpreted with caution. 
 Strong evidence of reliability and validity was reviewed for three measures – HIT-6, MSQv2.1 
and the PPMQ-R – supporting recommendation for consideration in future clinical research 
or routine practice settings. However, unlike the MSQv2.1 and PPMQ-R, patients were not 
involved in item generation for the HIT-6. 
 The review has highlighted significant heterogeneity in outcome reporting in headache 
studies, raising concerns over reporting bias and limiting the conduct of systematic reviews 
and meta-analyses of evidence. International multi-perspective consensus on the most 
important outcomes – both which outcomes and how to assess – is required, and can be 
supported by the findings from this review.  
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Headache Review – Cephalalgia 
Appendix 1.1 : Search strategies: Construct searches 
Database: Embase Classic+Embase <1947 to 2017 Week 16> 
Search Strategy: 
-------------------------------------------------------------------------------- 
1     exp chronic daily headache/ or exp episodic tension headache/ or exp headache/ or exp primary headache/ or exp chronic tension headache/ or exp new daily persistent headache/ or exp 
secondary headache/ or exp tension headache/ (201706) 
2     (headache* or migraine*).ti,ab. (136921) 
3     (headache* adj3 (mixed or combination or tension or tension type or muscle contraction or psychomyogenic or stress or ordinary or essential or psychogenic)).tw. (6527) 
4     ((chronic adj2 daily adj2 headache*) or (daily adj2 persistent adj2 headache*)).ti,ab. (1530) 
5     long term headache*.tw. (43) 
6     1 or 2 or 3 or 4 or 5 (244190) 
7     (daily or persistent or chronic).mp. (2456082) 
8     6 and 7 (56510) 
9     exp migraine aura/ or exp ophthalmoplegic migraine/ or exp migraine/ or exp migraine with aura/ or exp migraine without aura/ (57058) 
10     ((withdrawal or overuse or "over use" or "over-use" or misuse or "mis-use" or abuse or induced) adj5 (medication* or medicine* or analges* or drug* or opiate* or opioid* or nsaids or non-
opiate* or non opiate or ergot* or painkiller* or pain killer* or pain-killer*) adj5 (headache* or migraine*)).mp. (20637) 
11     ((rebound or transformed) adj5 (headache* or migraine*)).ti,ab. (450) 
12     8 or 9 or 10 or 11 (119498) 
13     (HR-PRO or HRPRO or HRPRO or HRQL or HRQoL or QL or QoL).mp. (73860) 
14     (quality of life or life quality).tw. (310350) 
15     (health index or health indices or health profile).mp. (5057) 
16     (patient or self or child or parent or carer or proxy).mp. (8459912) 
17     (report or reported or reporting or rated or rating or ratings or based or assessed or assessment assessments or disability or function or functional or functions or subjective or utility or 
utilities or wellbeing or well being).mp. (12222752) 
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18     (index or indices or instrument or instruments or measure or measures or questionnaire or questionnaires or profile or profiles or scale or scales or score or scores or status or survey or 
surveys).ti,ab. (5157109) 
19     health related quality of life.ti,ab. (44869) 
20     quality adjusted life year.ti,ab. (5178) 
21     QALY.tw. (11466) 
22     value of life.tw. (309) 
23     ((health adj2 utility*) or disutili*).mp. (2799) 
24     willingness to pay.tw. (5728) 
25     contingent valuation.tw. (697) 
26     standard gamble.tw. (945) 
27     SG.tw. (11070) 
28     time tradeoff.tw. (250) 
29     time trade off.tw. (1369) 
30     TTO.tw. (1299) 
31     mapping.tw. (161946) 
32     cross walking.tw. (17) 
33     transfer to utility.tw. (12) 
34     13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 (17788699) 
35     exp 'intermethod comparison'/ or exp 'data collection method'/ or exp 'validation study'/ or exp 'feasibility study'/ or exp 'pilot study'/ or exp 'psychometry'/ or exp 'reproducibility'/ or 
reproducib*.ab,ti. or 'audit'.ab,ti. or psychometr*.ab,ti. or clinimetr*.ab,ti. or clinometr*.ab,ti. or exp 'observer variation'/ or 'observer variation'.ab,ti. or exp 'discriminant analysis'/ or exp 
'validity'/ or reliab*.ab,ti. or valid*.ab,ti. or 'coefficient'.ab,ti. or 'internal consistency'.ab,ti. or (cronbach* and ('alpha' or 'alphas')).ab,ti. or 'item correlation'.ab,ti. or 'item correlations'.ab,ti. or 
'item selection'.ab,ti. or 'item selections'.ab,ti. or 'item reduction'.ab,ti. or 'item reductions'.ab,ti. or 'agreement'.ab,ti. or 'precision'.ab,ti. or 'imprecision'.ab,ti. or 'precise values'.ab,ti. or 'test-
retest'.ab,ti. or ('test' and 'retest').ab,ti. or (reliab* and ('test' or 'retest')).ab,ti. or 'stability'.ab,ti. or 'interrater'.ab,ti. or 'inter-rater'.ab,ti. or 'intrarater'.ab,ti. or 'intra-rater'.ab,ti. or 
'intertester'.ab,ti. or 'inter-tester'.ab,ti. or 'intratester'.ab,ti. or 'intra- tester'.ab,ti. or 'interobeserver'.ab,ti. or 'inter-observer'.ab,ti. or 'intraobserver'.ab,ti. or 'intra- observer'.ab,ti. or 
'intertechnician'.ab,ti. or 'inter-technician'.ab,ti. or 'intratechnician'.ab,ti. or 'intra- technician'.ab,ti. or 'interexaminer'.ab,ti. or 'inter-examiner'.ab,ti. or 'intraexaminer'.ab,ti. or 'intra- 
examiner'.ab,ti. or 'interassay'.ab,ti. or 'inter-assay'.ab,ti. or 'intraassay'.ab,ti. or 'intra-assay'.ab,ti. or 'interindividual'.ab,ti. or 'inter-individual'.ab,ti. or 'intraindividual'.ab,ti. or 'intra-
individual'.ab,ti. or 'interparticipant'.ab,ti. or 'inter-participant'.ab,ti. or 'intraparticipant'.ab,ti. or 'intra- participant'.ab,ti. or 'kappa'.ab,ti. or 'kappas'.ab,ti. or 'coefficient of variation'.ab,ti. or 
repeatab*.ab,ti. or ((replicab* or 'repeated') and ('measure' or 'measures' or 'findings' or 'result' or 'results' or 'test' or 'tests')).ab,ti. or generaliza*.ab,ti. or generalisa*.ab,ti. or 'concordance'.ab,ti. 
or ('intraclass' and correlation*).ab,ti. or 'discriminative'.ab,ti. or 'known group'.ab,ti. or 'factor analysis'.ab,ti. or 'factor analyses'.ab,ti. or 'factor structure'.ab,ti. or 'factor structures'.ab,ti. or 
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'dimensionality'.ab,ti. or subscale*.ab,ti. or 'multitrait scaling analysis'.ab,ti. or 'multitrait scaling analyses'.ab,ti. or 'item discriminant'.ab,ti. or 'interscale correlation'.ab,ti. or 'interscale 
correlations'.ab,ti. or (('error' or 'errors') and (measure* or correlat* or evaluat* or 'accuracy' or 'accurate' or 'precision' or 'mean')).ab,ti. or 'individual variability'.ab,ti. or 'interval variability'.ab,ti. 
or 'rate variability'.ab,ti. or 'variability analysis'.ab,ti. or ('uncertainty' and ('measurement' or 'measuring')).ab,ti. or 'standard error of measurement'.ab,ti. or sensitiv*.ab,ti. or responsive*.ab,ti. or 
('limit' and 'detection').ab,ti. or 'minimal detectable concentration'.ab,ti. or interpretab*.ab,ti. or (small* and ('real' or 'detectable') and ('change' or 'difference')).ab,ti. or 'meaningful change'.ab,ti. 
or 'minimal important change'.ab,ti. or 'minimal important difference'.ab,ti. or 'minimally important change'.ab,ti. or 'minimally important difference'.ab,ti. or 'minimal detectable change'.ab,ti. or 
'minimal detectable difference'.ab,ti. or 'minimally detectable change'.ab,ti. or 'minimally detectable difference'.ab,ti. or 'minimal real change'.ab,ti. or 'minimal real difference'.ab,ti. or 'minimally 
real change'.ab,ti. or 'minimally real difference'.ab,ti. or 'ceiling effect'.ab,ti. or 'floor effect'.ab,ti. or 'item response model'.ab,ti. or 'irt'.ab,ti. or 'rasch'.ab,ti. or 'differential item functioning'.ab,ti. or 
'dif'.ab,ti. or 'computer adaptive testing'.ab,ti. or 'item bank'.ab,ti. or 'cross-cultural equivalence'.ab,ti. (5156030) 
36     (addresses or biography or case reports or comment or directory or editorial or festschrift or interview or lectures or legal cases or legislation or letter or news or newspaper article or patient 
education handout or popular works or congresses or consensus development conference or consensus development conference, nih or practice guideline).pt. not (*animals/ not *humans/) 
(1526497) 
37     (12 and 34 and 35) not 36 (20124) 
38     limit 37 to (human and english language and (adult <18 to 64 years> or aged <65+ years>)) (10502) 
39     limit 38 to yr="1980 - 2016" (10296) 
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Database: Ovid MEDLINE(R) <1946 to April Week 2 2017> 
Search Strategy: 
-------------------------------------------------------------------------------- 
1     Headache/ (26018) 
2     exp headache disorders/ or exp headache disorders, primary/ (32133) 
3     exp Tension-Type Headache/ (1860) 
4     (headache* adj3 (mixed or combination or tension or tension type or muscle contraction* or psychomyogenic or stress or ordinary or essential or psychogenic)).tw. (4133) 
5     ((chronic adj2 daily adj2 headache*) or (daily adj2 persistent adj2 headache*)).ti,ab. (950) 
6     (headache* or hemicrania simplex).mp. (74687) 
7     long term headache*.mp. (19) 
8     chronic headache*.mp. (1518) 
9     exp Headache Disorders/ (32133) 
10     tension headache*.mp. (1004) 
11     1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 (88376) 
12     (daily or persistent or chronic).mp. (1583660) 
13     11 and 12 (17326) 
14     migraine*.mp. or exp Migraine with Aura/ or exp Migraine Disorders/ or exp Ophthalmoplegic Migraine/ or exp Migraine without Aura/ (32683) 
15     (withdrawal or overuse or "over use" or "over-use" or misuse or "mis-use" or abuse or induced).mp. adj5 (medication* or medicine* or analges* or drug* or opiate* or opioid* or NSAIDS or 
non-opiate* or non opiate* or ergot* or painkiller* or pain killer* or pain-killer*).ti,ab. adj5 (headache* or migraine*).ti,ab. (3474) 
16     ((rebound or transformed) adj5 (headache* or migraine*)).ti,ab. (327) 
17     13 or 14 or 15 or 16 (45932) 
18     (HR-PRO or HRPRO or HRPRO or HRQL or HRQoL or QL or QoL or PRO or PROs or PROM or PROMs).mp. (189311) 
19     (quality of life or life quality).mp. (228883) 
20     (health index* or health indices or health profile* or health status).mp. (128028) 
21     ((patient or self or proxy) adj (appraisal* or appraised or report or reported or reporting or rated or rating or ratings or based or assessed or assessment*)).mp. (155466) 
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22     ((disability or function or functional or functions or subjective or utility or utilities or wellbeing or well being or health) adj2 (index or indices or instrument or instruments or measure or 
measures or questionnaire* or profile or profiles or scale or scales or score or scores or status or survey or surveys)).ti,ab. (182045) 
23     health related quality of life.ti,ab. (27920) 
24     quality adjusted life year.ti,ab. (3358) 
25     QALY.tw. (5322) 
26     value of life.tw. (249) 
27     ((health adj2 utility*) or disutili*).mp. (1384) 
28     willingness to pay.tw. (3086) 
29     contingent valuation.tw. (498) 
30     standard gamble.tw. (749) 
31     SG.tw. (6571) 
32     time tradeoff.tw. (252) 
33     time trade off.tw. (884) 
34     TTO.tw. (746) 
35     mapping.tw. (122495) 
36     cross walking.tw. (6) 
37     transfer to utility.tw. (8) 
38     18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 (834011) 
39     (instrumentation or methods).sh. or Validation Stud- ies.pt. or Comparative Study.pt. or exp Psychometrics/ or psychometr*.ti,ab. or clinimetr*.tw. or clino- metr*.tw. or exp "Outcome 
Assessment (Health Care)"/ or outcome assessment.ti,ab. or outcome measure*.tw. or exp observer variation/ or observer variation.ti,ab. or exp Health Status Indicators/ or exp reproducibility of 
results/ or reproducib*.ti,ab. or exp discriminant analysis/ or reliab*.ti,ab. or unreliab*.ti,ab. or valid*.ti,ab. or coefficient.ti,ab. or homogeneity.ti,ab. or homogeneous.ti,ab. or internal 
consistency.ti,ab. or (cronbach* and (alpha or alphas)).ti,ab. or (item and (correlation* or selection* or reduction*)).ti,ab. or agreement.ti,ab. or precision.ti,ab. or imprecision.ti,ab. or "precise 
values".ti,ab. or test- retest.ti,ab. or (test and retest).ti,ab. or (reliab* and (test or retest)).ti,ab. or stability.ti,ab. or interrater.ti,ab. or inter-rater.ti,ab. or intrarater.ti,ab. or intra-rater.ti,ab. or 
intertester.ti,ab. or inter-tester.ti,ab. or intratester.ti,ab. or intra-tester.ti,ab. or interobserver.ti,ab. or inter-observer.ti,ab. or intraobserver.ti,ab. or intra- observer.ti,ab. or intertechnician.ti,ab. or 
inter-techni- cian.ti,ab. or intratechnician.ti,ab. or intra-technician.ti,ab. or interexaminer.ti,ab. or inter-examiner.ti,ab. or intraex- aminer.ti,ab. or intra-examiner.ti,ab. or interassay.ti,ab. or inter-
assay.ti,ab. or intraassay.ti,ab. or intra-assay.ti,ab. or interindividual.ti,ab. or inter-individual.ti,ab. or intraindi- vidual.ti,ab. or intra-individual.ti,ab. or interparticipant.ti,ab. or inter-participant.ti,ab. 
or intraparticipant.ti,ab. or intra-participant.ti,ab. or kappa.ti,ab. or kappa-s.ti,ab. or kappas.ti,ab. or repeatab*.ti,ab. or ((replicab* or repeated) and (measure or measures or findings or result or 
results or test or tests)).ti,ab. or generaliza*.ti,ab. or general- isa*.ti,ab. or concordance.ti,ab. or (intraclass and correlation*).ti,ab. or discriminative.ti,ab. or "known group".ti,ab. or factor 
analysis.ti,ab. or factor analyses.ti,ab. or dimension*.ti,ab. or subscale*.ti,ab. or (multitrait and scaling and (analysis or analyses)).ti,ab. or item discriminant.ti,ab. or interscale correlation*.ti,ab. or 
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error.ti,ab. or errors.ti,ab. or "individual variabil- ity".ti,ab. or (variability and (analysis or val- ues)).ti,ab. or (uncertainty and (measurement or measuring)).ti,ab. or "standard error of measure- 
ment".ti,ab. or sensitiv*.ti,ab. or responsive*.ti,ab. or ((minimal or minimally or clinical or clinically) and (important or significant or detectable) and (change or difference)).ti,ab. or (small* and (real 
or detectable) and (change or difference)).ti,ab. or meaningful change.ti,ab. or "ceiling effect".ti,ab. or "floor effect".ti,ab. or "Item response model".ti,ab. or IRT.ti,ab. or Rasch.ti,ab. or "Differential 
item functioning".ti,ab. or DIF.ti,ab. or "computer adaptive testing".ti,ab. or "item bank".ti,ab. or "cross-cultural equivalence".ti,ab. (5772794) 
40     (addresses or biography or case reports or comment or directory or editorial or festschrift or interview or lectures or legal cases or legislation or letter or news or newspaper article or patient 
education handout or popular works or congresses or consensus development conference or consensus development conference, nih or practice guideline).pt. not (*animals/ not *humans/) 
(3636046) 
41     (17 and 38 and 39) not 40 (2028) 
42     limit 41 to (english language and humans and "all adult (19 plus years)") (1412) 
43     limit 42 to yr="1980 - 2016" (1405) 
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Appendix 1.2 Named measure searches 
Database: Embase Classic+Embase <1947 to 2017 Week 16> 
Search Strategy: 
-------------------------------------------------------------------------------- 
1     exp chronic daily headache/ or exp episodic tension headache/ or exp headache/ or exp primary headache/ or exp chronic tension headache/ or exp new daily persistent headache/ or exp 
secondary headache/ or exp tension headache/ (201706) 
2     (headache* or migraine*).ti,ab. (136921) 
3     (headache* adj3 (mixed or combination or tension or tension type or muscle contraction or psychomyogenic or stress or ordinary or essential or psychogenic)).tw. (6527) 
4     ((chronic adj2 daily adj2 headache*) or (daily adj2 persistent adj2 headache*)).ti,ab. (1530) 
5     long term headache*.tw. (43) 
6     1 or 2 or 3 or 4 or 5 (244190) 
7     (daily or persistent or chronic).mp. (2456082) 
8     6 and 7 (56510) 
9     exp migraine aura/ or exp ophthalmoplegic migraine/ or exp migraine/ or exp migraine with aura/ or exp migraine without aura/ (57058) 
10     ((withdrawal or overuse or "over use" or "over-use" or misuse or "mis-use" or abuse or induced) adj5 (medication* or medicine* or analges* or drug* or opiate* or opioid* or nsaids or non-
opiate* or non opiate or ergot* or painkiller* or pain killer* or pain-killer*) adj5 (headache* or migraine*)).mp. (20637) 
11     ((rebound or transformed) adj5 (headache* or migraine*)).ti,ab. (450) 
12     8 or 9 or 10 or 11 (119498) 
13     exp 'intermethod comparison'/ or exp 'data collection method'/ or exp 'validation study'/ or exp 'feasibility study'/ or exp 'pilot study'/ or exp 'psychometry'/ or exp 'reproducibility'/ or 
reproducib*.ab,ti. or 'audit'.ab,ti. or psychometr*.ab,ti. or clinimetr*.ab,ti. or clinometr*.ab,ti. or exp 'observer variation'/ or 'observer variation'.ab,ti. or exp 'discriminant analysis'/ or exp 
'validity'/ or reliab*.ab,ti. or valid*.ab,ti. or 'coefficient'.ab,ti. or 'internal consistency'.ab,ti. or (cronbach* and ('alpha' or 'alphas')).ab,ti. or 'item correlation'.ab,ti. or 'item correlations'.ab,ti. or 
'item selection'.ab,ti. or 'item selections'.ab,ti. or 'item reduction'.ab,ti. or 'item reductions'.ab,ti. or 'agreement'.ab,ti. or 'precision'.ab,ti. or 'imprecision'.ab,ti. or 'precise values'.ab,ti. or 'test-
retest'.ab,ti. or ('test' and 'retest').ab,ti. or (reliab* and ('test' or 'retest')).ab,ti. or 'stability'.ab,ti. or 'interrater'.ab,ti. or 'inter-rater'.ab,ti. or 'intrarater'.ab,ti. or 'intra-rater'.ab,ti. or 
'intertester'.ab,ti. or 'inter-tester'.ab,ti. or 'intratester'.ab,ti. or 'intra- tester'.ab,ti. or 'interobeserver'.ab,ti. or 'inter-observer'.ab,ti. or 'intraobserver'.ab,ti. or 'intra- observer'.ab,ti. or 
'intertechnician'.ab,ti. or 'inter-technician'.ab,ti. or 'intratechnician'.ab,ti. or 'intra- technician'.ab,ti. or 'interexaminer'.ab,ti. or 'inter-examiner'.ab,ti. or 'intraexaminer'.ab,ti. or 'intra- 
examiner'.ab,ti. or 'interassay'.ab,ti. or 'inter-assay'.ab,ti. or 'intraassay'.ab,ti. or 'intra-assay'.ab,ti. or 'interindividual'.ab,ti. or 'inter-individual'.ab,ti. or 'intraindividual'.ab,ti. or 'intra-
individual'.ab,ti. or 'interparticipant'.ab,ti. or 'inter-participant'.ab,ti. or 'intraparticipant'.ab,ti. or 'intra- participant'.ab,ti. or 'kappa'.ab,ti. or 'kappas'.ab,ti. or 'coefficient of variation'.ab,ti. or 
repeatab*.ab,ti. or ((replicab* or 'repeated') and ('measure' or 'measures' or 'findings' or 'result' or 'results' or 'test' or 'tests')).ab,ti. or generaliza*.ab,ti. or generalisa*.ab,ti. or 'concordance'.ab,ti. 
or ('intraclass' and correlation*).ab,ti. or 'discriminative'.ab,ti. or 'known group'.ab,ti. or 'factor analysis'.ab,ti. or 'factor analyses'.ab,ti. or 'factor structure'.ab,ti. or 'factor structures'.ab,ti. or 
'dimensionality'.ab,ti. or subscale*.ab,ti. or 'multitrait scaling analysis'.ab,ti. or 'multitrait scaling analyses'.ab,ti. or 'item discriminant'.ab,ti. or 'interscale correlation'.ab,ti. or 'interscale 
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correlations'.ab,ti. or (('error' or 'errors') and (measure* or correlat* or evaluat* or 'accuracy' or 'accurate' or 'precision' or 'mean')).ab,ti. or 'individual variability'.ab,ti. or 'interval variability'.ab,ti. 
or 'rate variability'.ab,ti. or 'variability analysis'.ab,ti. or ('uncertainty' and ('measurement' or 'measuring')).ab,ti. or 'standard error of measurement'.ab,ti. or sensitiv*.ab,ti. or responsive*.ab,ti. or 
('limit' and 'detection').ab,ti. or 'minimal detectable concentration'.ab,ti. or interpretab*.ab,ti. or (small* and ('real' or 'detectable') and ('change' or 'difference')).ab,ti. or 'meaningful change'.ab,ti. 
or 'minimal important change'.ab,ti. or 'minimal important difference'.ab,ti. or 'minimally important change'.ab,ti. or 'minimally important difference'.ab,ti. or 'minimal detectable change'.ab,ti. or 
'minimal detectable difference'.ab,ti. or 'minimally detectable change'.ab,ti. or 'minimally detectable difference'.ab,ti. or 'minimal real change'.ab,ti. or 'minimal real difference'.ab,ti. or 'minimally 
real change'.ab,ti. or 'minimally real difference'.ab,ti. or 'ceiling effect'.ab,ti. or 'floor effect'.ab,ti. or 'item response model'.ab,ti. or 'irt'.ab,ti. or 'rasch'.ab,ti. or 'differential item functioning'.ab,ti. or 
'dif'.ab,ti. or 'computer adaptive testing'.ab,ti. or 'item bank'.ab,ti. or 'cross-cultural equivalence'.ab,ti. (5156030) 
14     (burden of migraine questionnaire or BURMIG or (beck depression inventory or BDI) or (comprehensive headache related quality of life questionnaire or CHQQ) or (completeness of response 
survey or CORS) or (cognitive impairment scale for migraine attacks or MIG-SCOG) or (chronic pain coping inventory or CPCI) or (depression anxiety stress scale or DASS) or (functional assessment in 
migraine or FAIM or FAIMQ) or (female sexual function index or FSFI) or (health utilities index or HUI) or (headache impact test or HIT 6 or HIT6 or HIT-6) or (headache impact score or HIS) or 
(headache management self-efficacy scale or HSES) or (headache-specific locus of control or headache specific locus of control) or (headache disability inventory or HDI) or (headache disability 
scale or HDS) or ((hospital anxiety and depression scale) or HADS) or ((headache-attributed restriction, disability, social handicap and impaired participation questionnaire) or HARDSHIP or 
HARDSHIPQ) or (headache activities of daily living index or HADLI) or (headache under response to treatment questionnaire or HURT or HURTQ) or (headache impact questionnaire or HIQ or HImQ) 
or (headache needs assessment survey or HANA) or (headache intensity or headache duration or headache severity) or (henry ford hospital headache disability inventory or HDI) or (impact of 
migraine-tension type headache-neck pain or Impact M-TTH-NP) or (italian perceived disability scale or IPDS) or (migraine treatment optimisation questionnaire or M-TOQ-15) or (migraine 
treatment satisfaction measure or MTSM) or (migraine-specific quality of life scale or MSQoL) or ((migraine work and productivity loss questionnaire) or MWPLQ) or (migraine disability assessment 
score or MIDAS) or (migraine disability assessment questionnaire or MDAS) or (migraine screen questionnaire or MS-Q) or (migraine impact questionnaire or MIQ) or (migraine specific quality of life 
questionnaire or MSQL or MSQ or MSQV 2 1) or (24-h MSQoLQ or 24-hour migraine specific quality of life questionnaire) or (patient perception of migraine questionnaire or PPMQ) or (patient 
health questionnaire or PHQ-9) or (pain disability index or PDI) or (pittsburg sleep quality index or PSQI) or (subjects global impression of change or SGIC) or (pain catastrophizing scale or PCS) or 
(visual aura rating scale or VARS) or (waters headache questionnaire or WHQ) or (numerical rating scale or NRS or numerical pain intensity scale or numerical pain rating scale or numeric rating 
scale for pain or NRS pain or NRS-pain) or (visual analogue scale or visual analogue scale for pain or VAS pain or VAS-pain or VAS) or (rating scale or analogue scale) or (SF36 or SF 36 or SF-36 or 
short form 36 or shortform 36 or short-form 36) or (SF12 or SF 12 or SF-12 or short form 12 or shortform 12 or short-form 12) or (SF6D or SF 6D or SF-6D or short form 6D or shortform 6D or short-
form 6D) or (euroqol or euro qol or euro-qol or EQ5D or EQ 5D or EQ-5D)).tw. (552600) 
15     (addresses or biography or case reports or comment or directory or editorial or festschrift or interview or lectures or legal cases or legislation or letter or news or newspaper article or patient 
education handout or popular works or congresses or consensus development conference or consensus development conference, nih or practice guideline).pt. not (*animals/ not *humans/) 
(1526497) 
16     (12 and 13 and 14) not 15 (3250) 
17     limit 16 to (human and english language and (adult <18 to 64 years> or aged <65+ years>)) (1794) 
18     limit 17 to yr="1980 - 2016" (1760) 
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Database: Ovid MEDLINE(R) <1946 to April Week 2 2017> 
Search Strategy: 
-------------------------------------------------------------------------------- 
1     Headache/ (26018) 
2     exp headache disorders/ or exp headache disorders, primary/ (32133) 
3     exp Tension-Type Headache/ (1860) 
4     (headache* adj3 (mixed or combination or tension or tension type or muscle contraction* or psychomyogenic or stress or ordinary or essential or psychogenic)).tw. (4133) 
5     ((chronic adj2 daily adj2 headache*) or (daily adj2 persistent adj2 headache*)).ti,ab. (950) 
6     (headache* or hemicrania simplex).mp. (74687) 
7     long term headache*.mp. (19) 
8     chronic headache*.mp. (1518) 
9     exp Headache Disorders/ (32133) 
10     tension headache*.mp. (1004) 
11     1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 (88376) 
12     (daily or persistent or chronic).mp. (1583660) 
13     11 and 12 (17326) 
14     migraine*.mp. or exp Migraine with Aura/ or exp Migraine Disorders/ or exp Ophthalmoplegic Migraine/ or exp Migraine without Aura/ (32683) 
15     (withdrawal or overuse or "over use" or "over-use" or misuse or "mis-use" or abuse or induced).mp. adj5 (medication* or medicine* or analges* or drug* or opiate* or opioid* or NSAIDS or 
non-opiate* or non opiate* or ergot* or painkiller* or pain killer* or pain-killer*).ti,ab. adj5 (headache* or migraine*).ti,ab. (3474) 
16     ((rebound or transformed) adj5 (headache* or migraine*)).ti,ab. (327) 
17     13 or 14 or 15 or 16 (45932) 
18     (instrumentation or methods).sh. or Validation Stud- ies.pt. or Comparative Study.pt. or exp Psychometrics/ or psychometr*.ti,ab. or clinimetr*.tw. or clino- metr*.tw. or exp "Outcome 
Assessment (Health Care)"/ or outcome assessment.ti,ab. or outcome measure*.tw. or exp observer variation/ or observer variation.ti,ab. or exp Health Status Indicators/ or exp reproducibility of 
results/ or reproducib*.ti,ab. or exp discriminant analysis/ or reliab*.ti,ab. or unreliab*.ti,ab. or valid*.ti,ab. or coefficient.ti,ab. or homogeneity.ti,ab. or homogeneous.ti,ab. or internal 
consistency.ti,ab. or (cronbach* and (alpha or alphas)).ti,ab. or (item and (correlation* or selection* or reduction*)).ti,ab. or agreement.ti,ab. or precision.ti,ab. or imprecision.ti,ab. or "precise 
values".ti,ab. or test- retest.ti,ab. or (test and retest).ti,ab. or (reliab* and (test or retest)).ti,ab. or stability.ti,ab. or interrater.ti,ab. or inter-rater.ti,ab. or intrarater.ti,ab. or intra-rater.ti,ab. or 
intertester.ti,ab. or inter-tester.ti,ab. or intratester.ti,ab. or intra-tester.ti,ab. or interobserver.ti,ab. or inter-observer.ti,ab. or intraobserver.ti,ab. or intra- observer.ti,ab. or intertechnician.ti,ab. or 
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inter-techni- cian.ti,ab. or intratechnician.ti,ab. or intra-technician.ti,ab. or interexaminer.ti,ab. or inter-examiner.ti,ab. or intraex- aminer.ti,ab. or intra-examiner.ti,ab. or interassay.ti,ab. or inter-
assay.ti,ab. or intraassay.ti,ab. or intra-assay.ti,ab. or interindividual.ti,ab. or inter-individual.ti,ab. or intraindi- vidual.ti,ab. or intra-individual.ti,ab. or interparticipant.ti,ab. or inter-participant.ti,ab. 
or intraparticipant.ti,ab. or intra-participant.ti,ab. or kappa.ti,ab. or kappa-s.ti,ab. or kappas.ti,ab. or repeatab*.ti,ab. or ((replicab* or repeated) and (measure or measures or findings or result or 
results or test or tests)).ti,ab. or generaliza*.ti,ab. or general- isa*.ti,ab. or concordance.ti,ab. or (intraclass and correlation*).ti,ab. or discriminative.ti,ab. or "known group".ti,ab. or factor 
analysis.ti,ab. or factor analyses.ti,ab. or dimension*.ti,ab. or subscale*.ti,ab. or (multitrait and scaling and (analysis or analyses)).ti,ab. or item discriminant.ti,ab. or interscale correlation*.ti,ab. or 
error.ti,ab. or errors.ti,ab. or "individual variabil- ity".ti,ab. or (variability and (analysis or val- ues)).ti,ab. or (uncertainty and (measurement or measuring)).ti,ab. or "standard error of measure- 
ment".ti,ab. or sensitiv*.ti,ab. or responsive*.ti,ab. or ((minimal or minimally or clinical or clinically) and (important or significant or detectable) and (change or difference)).ti,ab. or (small* and (real 
or detectable) and (change or difference)).ti,ab. or meaningful change.ti,ab. or "ceiling effect".ti,ab. or "floor effect".ti,ab. or "Item response model".ti,ab. or IRT.ti,ab. or Rasch.ti,ab. or "Differential 
item functioning".ti,ab. or DIF.ti,ab. or "computer adaptive testing".ti,ab. or "item bank".ti,ab. or "cross-cultural equivalence".ti,ab. (5772794) 
19     (burden of migraine questionnaire or BURMIG or (beck depression inventory or BDI) or (comprehensive headache related quality of life questionnaire or CHQQ) or (completeness of response 
survey or CORS) or (cognitive impairment scale for migraine attacks or MIG-SCOG) or (chronic pain coping inventory or CPCI) or (depression anxiety stress scale or DASS) or (functional assessment in 
migraine or FAIM or FAIMQ) or (female sexual function index or FSFI) or (health utilities index or HUI) or (headache impact test or HIT 6 or HIT6 or HIT-6) or (headache impact score or HIS) or 
(headache management self-efficacy scale or HSES) or (headache-specific locus of control or headache specific locus of control) or (headache disability inventory or HDI) or (headache disability 
scale or HDS) or ((hospital anxiety and depression scale) or HADS) or ((headache-attributed restriction, disability, social handicap and impaired participation questionnaire) or HARDSHIP or 
HARDSHIPQ) or (headache activities of daily living index or HADLI) or (headache under response to treatment questionnaire or HURT or HURTQ) or (headache impact questionnaire or HIQ or HImQ) 
or (headache needs assessment survey or HANA) or (headache intensity or headache duration or headache severity) or (henry ford hospital headache disability inventory or HDI) or (impact of 
migraine-tension type headache-neck pain or Impact M-TTH-NP) or (italian perceived disability scale or IPDS) or (migraine treatment optimisation questionnaire or M-TOQ-15) or (migraine 
treatment satisfaction measure or MTSM) or (migraine-specific quality of life scale or MSQoL) or ((migraine work and productivity loss questionnaire) or MWPLQ) or (migraine disability assessment 
score or MIDAS) or (migraine disability assessment questionnaire or MDAS) or (migraine screen questionnaire or MS-Q) or (migraine impact questionnaire or MIQ) or (migraine specific quality of life 
questionnaire or MSQL or MSQ or MSQV 2 1) or (24-h MSQoLQ or 24-hour migraine specific quality of life questionnaire) or (patient perception of migraine questionnaire or PPMQ) or (patient 
health questionnaire or PHQ-9) or (pain disability index or PDI) or (pittsburg sleep quality index or PSQI) or (subjects global impression of change or SGIC) or (pain catastrophizing scale or PCS) or 
(visual aura rating scale or VARS) or (waters headache questionnaire or WHQ) or (numerical rating scale or NRS or numerical pain intensity scale or numerical pain rating scale or numeric rating 
scale for pain or NRS pain or NRS-pain) or (visual analogue scale or visual analogue scale for pain or VAS pain or VAS-pain or VAS) or (rating scale or analogue scale) or (SF36 or SF 36 or SF-36 or 
short form 36 or shortform 36 or short-form 36) or (SF12 or SF 12 or SF-12 or short form 12 or shortform 12 or short-form 12) or (SF6D or SF 6D or SF-6D or short form 6D or shortform 6D or short-
form 6D) or (euroqol or euro qol or euro-qol or EQ5D or EQ 5D or EQ-5D)).tw. (315280) 
20     (addresses or biography or case reports or comment or directory or editorial or festschrift or interview or lectures or legal cases or legislation or letter or news or newspaper article or patient 
education handout or popular works or congresses or consensus development conference or consensus development conference, nih or practice guideline).pt. not (*animals/ not *humans/) 
(3636046) 
21     (17 and 18 and 19) not 20 (1566) 
22     limit 21 to (english language and humans and "all adult (19 plus years)") (1255) 
23     limit 22 to yr="1980 - 2016" (1243) 
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Appendix 1.3 List of measures included in ‘named PROM’ searches (EMBASE and MEDLINE) (Total n= 51) 
(burden of migraine questionnaire or BURMIG or  
(beck depression inventory or BDI) or  
(comprehensive headache related quality of life questionnaire or CHQQ) or  
(completeness of response survey or CORS) or  
(cognitive impairment scale for migraine attacks or MIG-SCOG) or  
(chronic pain coping inventory or CPCI) or  
(depression anxiety stress scale or DASS) or  
(functional assessment in migraine or FAIM or FAIMQ) or  
(female sexual function index or FSFI) or  
(health utilities index or HUI) or  
(headache impact test or HIT 6 or HIT6 or HIT-6) or  
(headache impact score or HIS) or  
(headache management self-efficacy scale or HSES) or  
(headache-specific locus of control or headache specific locus of control) or  
(headache disability inventory or HDI) or  
(headache disability scale or HDS) or  
((hospital anxiety and depression scale) or HADS) or  
12 
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((headache-attributed restriction, disability, social handicap and impaired participation questionnaire) or  
HARDSHIP or HARDSHIPQ) or  
(headache activities of daily living index or HADLI) or  
(headache under response to treatment questionnaire or HURT or HURTQ) or  
(headache impact questionnaire or HIQ or HImQ) or  
(headache needs assessment survey or HANA) or  
(headache intensity or headache duration or headache severity) or  
(henry ford hospital headache disability inventory or HDI) or  
(impact of migraine-tension type headache-neck pain or Impact M-TTH-NP) or  
(italian perceived disability scale or IPDS) or  
(migraine treatment optimisation questionnaire or M-TOQ-15) or  
(migraine treatment satisfaction measure or MTSM) or  
(migraine-specific quality of life scale or MSQoL) or  
((migraine work and productivity loss questionnaire) or MWPLQ) or  
(migraine disability assessment score or MIDAS) or  
(migraine disability assessment questionnaire or MDAS) or  
(migraine screen questionnaire or MS-Q) or  
(migraine impact questionnaire or MIQ) or  
13 
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(migraine specific quality of life questionnaire or MSQL or MSQ or MSQV 2 1) or  
(24-h MSQoLQ or 24-hour migraine specific quality of life questionnaire) or  
(patient perception of migraine questionnaire or PPMQ) or  
(patient health questionnaire or PHQ-9) or  
(pain disability index or PDI) or  
(pittsburg sleep quality index or PSQI) or  
(subjects global impression of change or SGIC) or  
(pain catastrophizing scale or PCS) or  
(visual aura rating scale or VARS) or  
(waters headache questionnaire or WHQ) or  
(numerical rating scale or NRS or numerical pain intensity scale or numerical pain rating scale or numeric rating scale for pain or NRS pain or NRS-pain) or  
(visual analogue scale or visual analogue scale for pain or VAS pain or VAS-pain or VAS) or  
(rating scale or analogue scale) or  
(SF36 or SF 36 or SF-36 or short form 36 or shortform 36 or short-form 36) or  
(SF12 or SF 12 or SF-12 or short form 12 or shortform 12 or short-form 12) or  
(SF6D or SF 6D or SF-6D or short form 6D or shortform 6D or short-form 6D) or  
(euroqol or euro qol or euro-qol or EQ5D or EQ 5D or EQ-5D)).tw. (552600) 
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Appendix 2. Table 1: Multi-item PROMs identified (n=39) from full-text articles assessed for eligibility (searched 1980-2016); n=23 PROMs included in final review (‘in-
use’ 2000-2016). 
PROM Developer / article in which identified 
 
Include / 
exclude 
from full 
review 
Justification  Evaluations 
included in 
review (n) 
 
Migraine-specific (10) 
 
5/10 
 1988-
1999 
Post-
2000 
BURMIG questionnaire Andree, C., M. Vaillant, C. Rott, Z. Katsarava and P. S. Sandor (2008). 
"Development of a self-reporting questionnaire, BURMIG, to evaluate the 
burden of migraine." Journal of Headache & Pain 9(5): 309-315. 
 
No 
 
Developed in Swiss population – evidence of 
translation into English not clear in article. Initial 
evaluation in Swiss population. Exclude.  
 
- (1) 
Functional Assessment 
in Migraine 
Questionnaire (FAIM) 
Pathak, D. S., D. J. Chisolm and K. A. Weis (2005). "Functional Assessment in 
Migraine (FAIM) questionnaire: development of an instrument based upon 
the WHO's International Classification of Functioning, Disability, and Health." 
Value in Health 8(5): 591-600. 
 
Yes Fulfils inclusion criteria - 1 
Headache Needs 
Assessment (HANA) 
survey 
Cramer, J. A., S. D. Silberstein and P. Winner (2001). "Development and 
validation of the headache needs assessment (HANA) survey." Headache 
41(4): 402-409. 
 
Yes Fulfils inclusion criteria - 1 
Migraine Disability 
Assessment Scale 
(MIDAS) 
Stewart, W. F., R. Lipton, K. Kolodner, J. Liberman and J. Sawyer (1999A). 
"Reliability of the migraine disability assessment score in a population- based 
sample of headache sufferers." Cephalalgia 19(2): 107-114. 
 
Yes Fulfils inclusion criteria 2 10 
Migraine Quality of life 
Questionnaire 
(MQoLQ) 
Hartmaier, S. L., N. C. Santanello, R. S. Epstein and S. D. Silberstein (1995). 
"Development of a brief 24-hour migraine-specific quality of life 
questionnaire." Headache 35(6): 320-329. 
 
No No evaluations identified post-2000. Used as a 
comparator in establishing evidence in support of a 
new measure – the MTSM – but this is limited [32].    
 
(1) 0 
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Migraine-specific 
Quality of Life 
Questionnaire (MSQ) 
v1. 
Jhingran, P., J. T. Osterhaus, D. W. Miller, J. T. Lee and L. Kirchdoerfer (1998). 
"Development and validation of the migraine-specific quality of life 
questionnaire." Headache 38(4): 295-302. 
 
No Succeeded by MSQ v2.1 (1) - 
Migraine-specific 
Quality of Life 
Questionnaire (MSQ) 
v2.  
Jhingran, P., S. M. Davis, L. M. LaVange, D. W. Miller and R. W. Helms (1998). 
"MSQ: Migraine-specific quality-of-life questionnaire: Further investigation of 
the factor structure." PharmacoEconomics 13(6): 707-717. 
No Succeeded by MSQ v2.1 (1) - 
Migraine-specific 
Quality of Life 
Questionnaire (MSQ) 
v2.1.  
Martin, B. C., D. S. Pathak, M. I. Sharfman, J. U. Adelman, F. Taylor, W. J. 
Kwong and P. Jhingran (2000). "Validity and reliability of the migraine-
specific quality of life questionnaire (MSQ Version 2.1)." Headache 40(3): 
204-215. 
 
Yes Fulfils inclusion criteria - 9 
Migraine-specific 
Quality of Life 
Questionnaire (MSQoL) 
Wagner, T. H., D. l. Patrick, B. S. Galer and R. A. Berzon (1996). "- A new 
instrument to assess the long-term quality of life effects from migraine: 
development and psychometric testing of the MSQOL." Headache 36(8): 
484-492. 
 
Yes Fulfils inclusion criteria 2 1 
Migraine Symptom 
Frequency Bother 
questionnaire 
Patrick, D. L., M. L. Martin, D. M. Bushnell and J. Pesa (2003). "Measuring 
satisfaction with migraine treatment: expectations, importance, outcomes, 
and global ratings." Clinical Therapeutics 25(11): 2920-2935. 
 
No Ad hoc measure developed specifically for single 
study. Not evaluated or applied again. 
- 1 
      
 
Headache-specific (8) 
 
6/8 
   
Comprehensive 
Headache Related 
Quality of Life 
Questionnaire (CHQQ) 
 
Manhalter, N., G. Bozsik, A. Palasti, E. Csepany and C. Ertsey (2012). "The 
validation of a new comprehensive headache-specific quality of life 
questionnaire." Cephalalgia 32(9): 668-682. 
No Non-Anglicised evaluations (n=2) - (2) 
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EUROLIGHT 
questionnaire 
Andree, C., Vallaint M., Barre, J.,Katsarava R. et al. (2009). “Development and 
Validation of the EUROLOGHT questionnaire to evaluate the burden of 
primary headache disorders in Europe.” Cephalalgia 30 (9):1082-1100. 
 
Yes Fulfils inclusion criteria - 1 
Headache Activities of 
Daily Living Index 
(HADLI) 
Vernon, H. and G. Lawson (2015). "Development of the headache activities 
of daily living index: Initial validity study." Journal of Manipulative and 
Physiological Therapeutics 38(2): 102-111. 
 
Yes Fulfils inclusion criteria - 1 
Headache Attributed 
Restriction, Disability, 
Social Handicap and 
Impaired 
Participation 
(HARDSHIP) 
questionnaire 
 
Steiner, T. J., G. Gururaj, C. Andree, Z. Katsarava, I. Ayzenberg, S. Y. Yu, M. Al 
Jumah, R. Tekle-Haimanot, G. L. Birbeck, A. Herekar, M. Linde, E. Mbewe, K. 
Manandhar, A. Risal, R. Jensen, L. P. Queiroz, A. I. Scher, S. J. Wang and L. J. 
Stovner (2014). "Diagnosis, prevalence estimation and burden measurement 
in population surveys of headache: presenting the HARDSHIP questionnaire." 
Journal of Headache and Pain 15(1). 
 
No 
 
Interview-administration only – modular instrument: 
demographic, diagnostic, headache-attributed 
burden – symptoms, health-care utilisation, 
disability, productive time loss, impact on education, 
career and earnings, control, relationships and 
family, qol, well-being, co-morbidities.  
- - 
Headache Disability 
Impact Questionnaire 
(HDI) 
 
Niere K, Quin A. Development of a headache-specific disability questionnaire 
for patients attending physiotherapy. Man Ther. 2009 Feb;14(1):45-51 
 
Yes Fulfils inclusion criteria - 1 
Headache Impact Test 
(HIT) 
Bjorner, J. B., M. Kosinski and J. E. Ware Jr (2003A). "Calibration of an item 
pool for assessing the burden of headaches: An application of item response 
theory to the Headache Impact Test (HITTM)." Quality of Life Research 12(8): 
913-933. 
 
Yes Fulfils inclusion criteria - 3 
Headache Impact Test-
6  (HIT-6) 
Bjorner, J. B., M. Kosinski and J. E. Ware Jr (2003C). "Using item response 
theory to calibrate the Headache Impact Test (HITTM) to the metric of 
traditional headache scales." Quality of Life Research 12(8): 981-1002. 
Yes Fulfils inclusion criteria - 12 
Henry Ford hospital 
headache disability 
inventory (HDI). 
Jacobson, G. P., N. M. Ramadan, S. K. Aggarwal and C. W. Newman (1994). 
"The Henry Ford hospital headache disability inventory (HDI)." Neurology 
44(5): 837-842. 
No No evaluations identified post-2000  - 
17 
 
CHESS PROM review FTC: Appendices Edited 270717 
 
 
SF-36 ‘Headache-
specific’ Modification 
 
Magnusson JE, Riess CM, Becker WJ. Modification of the SF-36 for a 
headache population changes patient-reported health status. Headache. 
2012; 52(6): 993-1004. 
 
Yes Fulfils inclusion criteria - 1 
 
Response to treatment (7) 
 
6/7 
   
Completeness of 
Response Survey 
(CORS) 
Coon, C. D., S. E. Fehnel, K. H. Davis, M. C. Runken, M. E. Beach and R. K. 
Cady (2012). "The development of a survey to measure completeness of 
response to migraine therapy." Headache 52(4): 550-572. 
 
Yes Fulfils inclusion criteria - 1 
Migraine Assessment 
of Current Therapy 
(Migraine-ACT) 
Questionnaire 
Dowson, A. J., S. J. Tepper, V. Baos, F. Baudet, D. D'Amico and S. Kilminster 
(2004). "Identifying patients who require a change in their current acute 
migraine treatment: The Migraine Assessment of Current Therapy (Migraine-
ACT) questionnaire." Current Medical Research and Opinion 20(7): 1125-
1135. 
 
Yes Fulfils inclusion criteria - 2 
Migraine Therapy 
Assessment 
Questionnaire  
(M-TAQ) 
 
Chatterton ML1, Lofland JH, Shechter A, Curtice WS, Hu XH, Lenow 
J, Smullens SN, Nash DB, Silberstein SD. 
Reliability and validity of the migraine therapy assessment questionnaire. 
Headache. 2002 Nov-Dec;42(10):1006-15. 
 
Yes Fulfils inclusion criteria - 1 
Migraine Therapy 
Optimisation 
Questionnaire  
(M-TOQ) 
Lipton, R. B., K. Kolodner, M. E. Bigal, D. Valade, M. J. A. Lainez, J. Pascual, A. 
Gendolla, G. Bussone, N. Islam, K. Albert and B. Parsons (2009). "Validity and 
reliability of the migraine-treatment optimization questionnaire." 
Cephalalgia 29(7): 751-759. 
 
Yes Fulfils inclusion criteria - 1 
Migraine Treatment 
Satisfaction Measure 
(MTSM) 
Patrick, D. L., M. L. Martin, D. M. Bushnell and J. Pesa (2003). "Measuring 
satisfaction with migraine treatment: expectations, importance, outcomes, 
and global ratings." Clinical Therapeutics 25(11): 2920-2935. 
Yes Fulfils inclusion criteria - 2 
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Patient Perception of 
Migraine 
Questionnaire (PPMQ) 
Davis, K. H., L. Black and B. Sleath (2002). "Validation of the Patient 
Perception of Migraine Questionnaire." Value in Health 5(5): 422-430. 
 
(Yes) Fulfils inclusion criteria – but succeeded by PPMQ-R - 1 
Patient Perception of 
Migraine 
Questionnaire – 
Revised (PPMQ-R) 
Revicki, D. A., M. Kimel, K. Beusterien, J. W. Kwong, J. A. Varner, (2006).  
 
Yes Fulfils inclusion criteria - 2 
      
 
Generic (8) 
 
6/8 
   
Generic quality of life / health status      
Profile measures (4)  3/4    
Short Form Health 
Survey 8 (SF-8) 
Turner-Bowker, D. M., M. S. Bayliss, J. E. Ware Jr and M. Kosinski (2003). 
"Usefulness of the SF-8TM Health Survey for comparing the impact of 
migraine and other conditions." Quality of Life Research 12(8): 1003-1012. 
 
Yes Fulfils inclusion criteria - 4 
Short Form Health 
Survey 12 (SF-12) 
Lipton, R. B., S. W. Hamelsky, K. B. Kolodner, T. J. Steiner and W. F. Stewart 
(2000). "Migraine, quality of life, and depression: a population-based case-
control study." Neurology 55(5): 629-635. 
 
Yes Fulfils inclusion criteria - 1 
Short Form Health 
Survey 36 (SF-36) 
Solomon, G. D., F. G. Skobieranda and L. A. Gragg (1993). "Quality of life and 
well-being of headache patients: measurement by the medical outcomes 
study instrument." Headache 33(7): 351-358. 
 
Yes Fulfils inclusion criteria - 5 
World Health 
Organisation Disability 
Assessment II (WHO-
DAS II) 
Raggi, A., M. Leonardi, G. Bussone and D. D'Amico (2011). "Value and utility 
of disease-specific and generic instruments for assessing disability in patients 
with migraine, and their relationships with health-related quality of life." 
Neurological Sciences 32(3): 387-392. 
No Non-Anglicised evaluations (n=3) - 3 
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Utility measures (4) 
  
3/4 
   
EuroQol EQ-5D-3L Essink-Bot, M. L., P. F. Krabbe, G. J. Bonsel and N. K. Aaronson (1997). “An 
empirical comparison of four generic health status measures. The 
Nottingham Health Profile, the Medical Outcomes Study 36-item Short-Form 
Health Survey, the COOP/WONCA charts, and the EuroQol instrument.” 
Medical care 35(5): 522-537. Non-Anglicised evaluation 
Anglicised evaluations included in review (n=3) 
 
Yes Fulfils inclusion criteria - 3 
Health Utilities Index 
(HUI) 
Mo, F., B. C. Choi, F. C. Li and J. Merrick (2004). "Using Health Utility Index 
(HUI) for measuring the impact on health-related quality of Life (HRQL) 
among individuals with chronic diseases." The Scientific World Journal 4: 746-
757. 
 
No Succeeded by HUI-3 - 1 
Health Utilities Index-3 
(HUI-3) 
Brown, J. S., P. J. Neumann, G. Papadopoulos, G. Ruoff, M. Diamond and J. 
Menzin (2008). "Migraine frequency and health utilities: findings from a 
multisite survey." Value in Health 11(2): 315-321. 
 
Yes Fulfils inclusion criteria - (1) 
Quality of Well Being 
Scale (QWB-8) 
Sieber, W. J., K. M. David, J. E. Adams, R. M. Kaplan and T. G. Ganiats (2000). 
"Assessing the impact of migraine on health-related quality of life: An 
additional use of the quality of well-being scale-self-administered." 
Headache 40(8): 662-671. 
 
Yes Fulfils inclusion criteria - 1 
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Appendix 3: Table 2: Assessment criteria for the quality of reported measurement properties [17,19,20]. 
Measurement property Rating Assessment of quality  
Reliability   
  Internal consistency  
- the extent to which items within a measure are 
internally consistent 
+ Cronbach’s alpha(s) > 0.70 
? Cronbach’s alpha not evaluated or dimensionality unknown 
- Cronbach’s alpha(s) < 0.70 
   
Reliability  
(test-retest / inter-rater / inter-rater)    
-  the extent to which a measure provides the same 
results on repeated completions, assuming no change in 
the underlying health state 
+ Intra-class Correlation Coefficient (ICC)/weighted Kappa >0.70 OR Pearson’s r >0.80 
? Neither ICC/weighted Kappa, not Pearson’s r evaluated 
- ICC/weighted Kappa <0.70 OR Pearson’s r <0.80 
   
Validity   
Content validity  
- the extent to which the item content of a measure is an 
adequate reflection of the construct being measured 
+ Authors provide a clear description of the measurement aim, target population, concept(s) measured and process of item selection. 
Members of the target population and experts in the field were clearly identified as being involved in development. For measures applied 
for the first time in a new population, evidence that the views of members of the target population (and experts in the field) have been 
sought to determine relevance, comprehension and comprehensiveness. 
? Insufficient evidence available 
- No detail re measurement aim, target population, concept(s) measured, process of item selection; members of the target population or 
experts were not specifically involved in development. 
For measures applied for the first time in a new population, evidence whereby the relevance and acceptability of the measure with 
members of the target audience or experts was not provided. 
   
Construct validity - Structural validity 
- the extent to which PROM scores adequately reflect the 
dimensionality of the construct being measured.   
+ Factors should explain 50% of the variance 
? Explained variance not reported 
- Factors explain < 50% of the variance 
   
 Construct validity - Hypothesis testing  
- convergent (the extent to which measures of related 
constructs are related to each other) 
+ Correlations with measures of the same construct should be >0.50 OR at least 75% of the results in accordance with hypothesized 
associations AND correlations with related constructs should be higher than with those reported with unrelated constructs  
? Only report correlations with unrelated constructs 
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- discriminant (the extent to which a measure can 
demonstrate differences between groups known to 
differ on important variables)  
- Correlations with measures of the same construct are <0.50 OR < 75% of the results in accordance with hypothesized associations OR 
correlations with related constructs are lower than those reported with unrelated constructs 
   
Responsiveness 
- the ability to detect important change over time in the 
construct being measured (criterion / construct-based 
assessment) 
+ Change-score correlations with measures of the same construct are >0.50 OR at least 75% of the results are in accordance with 
hypothesized associations OR the Area Under the Curve (AUC) is >0.70 AND change-score correlations with measures of related constructs 
are higher than those reported with unrelated constructs 
? Solely correlations with unrelated constructs 
- Change-score correlations with measure of the same construct <0.50 OR < 75% of the results are in accordance with hypothesized 
associations OR AUC is <0.70 AND change-score correlations with related constructs are lower than those reported with unrelated 
constructs 
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Appendix 4: Table 3 Characteristics of reviewed PROMs evaluated in the headache population (total = 23)  
PROM  
(Author; web-linkb; completion format) c 
Items 
na 
Construct 
 
Domains (items) 
Response options 
(range) 
Recall                      
Period 
Score range Administration 
Condition-specific (17)    Time 
Migraine-impact (5/17)     
Functional Assessment in Migraine  
(FAIM) 
 
(Pathak et al, 2005)[33] 
 
Self-completion  
Items listed in development paper 
9 + 5 Underpinned by the WHO ICF. 
Focus on the functional impact 
of migraine. 
 
3 domains: Two mental 
function: 
Attention/Thought (5): 
concentration, control of life, 
focus on issues, spontaneity, 
think quickly. 
Perception (4): find a peaceful 
place, light/sound/interaction 
avoidance. 
One overall domain: ‘Activity 
and Participation’(5): select up 
to 5 items from list of 28. 
 
Item stem: How much 
does each item 
impact on their lives? 
 
7-point scale: 1= ‘not 
at all’ to 7 – ‘all of the 
time’ 
Within 24-hours 
of their typical 
migraine onset 
Item summation within 
the three domains.  
 
A/T: range 5-35 
P: range 4-28 
A/P: range 5-35 
 
Lower scores indicate 
less functional impact.  
5-10 minutes 
 
Not reported in 
headache 
population 
Headache Needs Assessment  
(HANA) 
 
(Cramer et al,2001)[34] 
 
Self-completion 
Copy of PROM in appendix to paper 
7 Migraine quality of life – 
frequency and bothersomeness 
(7):  
Anxiety/worry; 
depression/discouragement; 
self-control; energy; 
function/work; family/social 
activities; overall impact of 
migraines. 
 
 
For each item: 
Frequency: How often 
has this problem 
occurred?: never / 
rarely / sometimes / 
often / all the time) 
Bothersomeness: How 
much has this 
problem bothered 
you?: not at all / a 
little / some / a lot / a 
great deal. 
Not stated Item summation. 
Total range 7-175, 
where lower scores 
indicate less impact. 
5-10 minutes 
 
Not reported in 
headache 
population 
Migraine Disability Assessment Score 
(MIDAS) 
 
(Stewart et al. 1999)[35] 
  
http://www.achenet.org/midas/ 
 
12 Migraine disability (but 
attribution is ‘headache’) 
 
3 domains (5 scored items) 
Missed days/ reduced 
productivity at paid work (2) 
Item stem: About ALL 
of the headaches you 
have had… 
 
Frequency - number 
of days/ half days of 
disability 
3 months Total score derived as 
sum of lost days, where 
greater number of days 
indicates greater 
migraine-related 
disability. 
5-10 minutes 
 
Not reported in 
headache 
population 
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Self-completion Missed days/ reduced 
productivity at household work 
(2) 
Missed non-work activities (1) 
 
Plus: 2 unscored items 
Frequency of headaches (how 
many days?) (1) 
Headache pain severity (1) 
 
 
 
 
 
 
Not scored: 
Number of days 
 
Scale 0-10 (0= no pain 
at all, and 10= pain as 
bad as can be) 
 
Migraine-Specific Quality of Life Questionnaire version 
2.1 
 
(MSQ v2.1) 
 
(Martin et al, 2000 [36] 
 
http://www.outcomes-
trust.org/instruments.htm#msql2.1 
 
Contact for further details and copy of questionnaire: 
michael.c.runken@gsk.com 
 
Self-completion 
9 Health-related quality of life - 
impairments attributed to 
migraine 
 
3 domains (14 items) 
Role function – Restrictive 
(RR)(7): social – family/friends; 
leisure (2); work/ADL(3); 
cognition (1); symptoms: 
fatigue (1) 
 
Role function – Preventive 
(RP)(4): symptoms: fatigue (1); 
work /ADL (2); social (1) 
 
Emotional function (EF)(3): 
frustration (1); feeling a burden 
(1); letting others down (1) 
 
 
 
 
Item stem: How often 
have migraines 
interfered with / 
limit/ed your ability to 
/ keep you from 
getting as much done 
/ had difficulty in / 
 
How often have you 
had to cancel / need 
help / have to stop / 
not able to go… … 
because of your 
migraine 
 
6-point categorical 
scale: 
None of the time (1), 
A little bit of the time 
(2), Some of the time 
(3), A good bit of the 
time (4), Most of the 
time (5), All of the 
time (6). 
 
4 weeks Items summed within 
the three domains and 
transformed to 0-100 
scale.  
 
Higher scores indicate a 
worse quality of life 
5-10 minutes 
 
Not reported in 
headache 
population 
Migraine-Specific Quality of life (MSQOL) measure 
 
(McKenna et al, 1998) [37] 
 
1 Needs-based migraine-specific 
quality of life  
 
3 domains (20 items): 
Item stems: Various – 
include: ‘I try to avoid 
…’ / ‘It’s important for 
Responders 
advised to 
‘choose the 
answer that 
All items summed 
(score range 20-80) and 
transformed to 0-100 
scale.  
5-10 minutes 
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http://www.galen-research.com/content/measures/ 
MSQoL%20UK%20-%20First%20page%20sample.pdf 
 
Payment required to access full version of the 
questionnaire 
 
Self-completion 
 
Avoidance behaviours (10) 
 
Social relations (6) 
 
Feelings (4) 
me…’ / ‘I feel helpless 
…’/ ‘I worry about …’ 
 
4-point categorical 
response scale: range:  
Yes, very much / I try 
very hard / very 
important (1) 
Yes, quite a lot / I try 
quite hard / quite 
important (2) 
A little / I do not try 
very hard / not very 
important (3)  
Not at all / I do not try 
at all / it’s not 
important at all (4)    
applies to you: 
between 
migraine attacks 
OR with any 
treatment you 
use now.  
 
 
Higher scores indicate 
better quality of life 
 
Not reported in 
headache 
population 
       
Headache-impact (6/17)     
EUROLIGHT  
 
(Andree et al, 2010)[28] 
 
http://www.l-t-b.org/index.cfm/spKey/publications.html 
 
Self-completion 
1 Burden of primary headache 
disorders. 
 
Includes assessment of 
headache characteristics, co 
morbidities, disease 
management and quality of life  
 
6 sections (103 items): 
1) Biographical (age, gender, 
language and employment)  
2) Screening questions for 
headache (life-time and 1-year 
prevalence) 
3) Diagnostic questions - based 
on the criteria of the 
International Classiﬁcation of 
Headache Disorders (ICHD-II) 
4) Questions about any 
headache experienced 
‘yesterday’ (point prevalence) 
5) Use of healthcare resources 
(medicines, investigations, 
consultations, etc.)  
All domains 
categorical response 
categories – various 
number of options 
Headache 
frequency in past 
month/yesterday 
 
Healthcare past 
30 days 
 
Headache impact 
on ‘own life’ 
 
Headache-
related lost time 
in past 3 months 
 
Various 
 
As per WHOQoL, HALT-
index and HADS. 
Not reported. 
 
Will require 
considerable 
completion time 
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6) Impact of headache on 
work, family life and social 
activities: includes items taken 
from the WHOQOL (8-items), 
the HALT-index and HADS. 
 
Headache Activities of Daily Living Index  
 
(HADLI)  
 
(Vernon & Lawson, 2015) [29] 
 
 
 
Self-completion 
1 Headache-related ‘activity 
disability’ - ability of an 
individual to engage with usual 
activities of daily life during 
headache episode 
 
1 domain (9 items):  
Personal care 
Lifting 
Reading (including computers) 
Sleeping (over last week) 
Exercising (over last week) 
Social activities 
Work 
Driving or travelling 
Recreation 
 
6-point categorical 
response options, 
where 0 is best ability 
and 5 is worst ability. 
 
   
During headache 
episode ‘when 
you have a 
headache’ 
Item summation: score 
range 0 to 45, where 45 
is maximum activity 
disability.  
 
Total score converted 
to percentage 
3 minutes 
Headache Disability Questionnaire 
 
(HDQ) 
 
(Niere & Quin, 2009) [30] 
 
 
Self-completion 
1 Headache specific disability in 
patients presenting for 
physiotherapy treatment 
 
3 domains (9 items): 
Pain (2): usual pain intensity; 
when pain is severe. 
 
Activity Limitation (4): 
Decreased efficiency in non-
work activities 
Decreased ability to 
work/study 
Decreased efficiency in 
housework or chores 
Proportion of times when work 
is missed 
 
Activity Prevention (3): 
Number of days where chores 
prevented  
11 point Numerical 
Rating Scales 
 
Anchors (0-10): 
Adjectival anchors:  
No pain (0) - Worst 
pain (10) 
Never (0) – Always 
(10) 
None (0) – Everyday 
(10) 
Not reduced (0) - 
Unable to work (10) 
Not reduced (0) - 
Unable to perform 
(10) 
Past 1-month Item summation. Index 
range 0-90, where 
higher scores indicate 
greater headache-
specific disability.  
?? 
26 
 
CHESS PROM review FTC: Appendices Edited 270717 
 
Number of days non-work 
activities prevented 
Number of days in last month 
when had to lie down for >1 
hour;  
 
Headache Impact Test (HIT) 
 
CAT-HIT 
(IRT-HIT) 
 
(Bjorner JB et al. 2003a [3]; Ware JE et al, 2003 [57]) 
 
Self-completion- requires internet interface for CAT 
completion 
3 Headache impact 
 
Items, derived from four 
established measures: 
MIDAS 
MSQ (v1.0) 
Headache Disability Index (HDI) 
Headache Impact 
Questionnaire (HIMQ) 
 
Plus experimental items 
generated from clinical trial 
data, and consultation with 
clinicians. 
 
One domain ‘Headache 
Impact’: 54-item ‘item bank’ 
Items cover a wide spectrum of 
headache impact, including 
minor headache. 
 
Items cover of pain, role and 
social functioning, 
energy/fatigue, cognitive 
function, and mental health 
 
Up to five categorical 
responses 
 
Internet completion 
only using 
Computerized 
Adaptive Testing 
(CAT): CAT-HIT  
1-month Scored using Item 
Response Methods 
(IRT) (also referred to 
as IRT-HIT). 
 
Number of completed 
items determined by 
‘stopping rule’: mean 
number 6/54 items. 
 
Norm-based scoring 
with mean 50 (SD 10), 
where higher scores 
indicate very severe 
headache impact. 
Approximate 
response times 
of 1.5 minutes 
for those with 
least headache 
impact (HIT 
scores < 50)  
 
Range from 2.4 
items/ minute 
for a 9-item 
survey to 3.3 
items/minute 
for a 6-item 
survey 
Headache Impact Test  
(HIT-6) 
 
(Kosinski et al, 2003a) [31]  
 
https://www.optum.com/optum-outcomes/what-we-
do/disease-specific-health-surveys/hit-6.html 
 
 
Self-completion 
8 Headache impact 
 
Static, short-form HIT: 6 
domains (6-items) 
Pain (headache - how often is 
the pain severe?) (1) 
Social functioning (limit your 
ability to do usual daily 
activities – work / adl / social?) 
(1) 
Equally weighted 5-
option categorical 
scale with specific 
item score (generated 
to closely match the 
IRT score) 
 
Item stem: ‘how 
often…?’ 
 
Attribution: ‘when you 
have a headache / 
3 items (Vitality; 
Psychological 
distress; 
Cognition): past 
4weeks  
 
2 items (Pain. 
Role limitation): 
‘when you have a 
headache’ 
 
Item summation to 
create index score: 
range 36-78 
  
Score interpretation 
(norm-based mean 50 
(SD 10)): 
>60: very severe impact 
 
56-59:  substantial 
impact 
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Role functioning (how often do 
you wish you could lie down?) 
(1) 
Vitality (too tired to do work or 
adl?) (1) 
Cognitive functioning (limit 
ability to concentrate on work 
or adl?) (1) 
Psychological distress (felt fed 
up or irritated) (1) 
because of your 
headache’ 
 
Range (weighted item 
responses):  
Never (6 points), 
Rarely (8 points), 
Sometimes (10 
points), Very Often 
(11 points), Always 
(13 points) 
 
1 item (Social 
function): how 
often do 
headaches limit 
… 
50-55: some impact 
 
49 or <: little or no 
impact 
‘Headache’ SF-36 
 
(Magnusson J.E. et al. 2012)[32] 
 
Self-completion 
1 Headache-related health status 
 
Modification of original SF-36 
to ‘improve applicability’ to the 
headache population by 
inserting ‘including your 
headaches’ to 6/36 items: 
physical functioning (item 3); 
role limitation - physical (item 
4); social functioning (items 6 
and 10); bodily pain (items 7 
and 8) 
 
Equally weighted 3 or 
5 point Likert Scale 
4 weeks or 1 
week 
Scale scores 
transformed to 0-100 
calibrated at 50 as the 
norm 
 
8 domains 
2 summary scales 
  
5-10 minutes 
       
Response to migraine-specific treatment (6/17)     
Completeness of Response to Migraine Therapy Survey 
 
(CORS) 
 
(Coon CD. et al. 2012) [38] 
 
Both versions of CORS illustrated in full in appendix to 
article 
 
Self-completion 
1 Optimal treatment: considers 
factors important to patients 
when considering the 
initiation/continuation of 
migraine treatment 
 
Two modules: 
 
1.‘Static CORS’ – to evaluate 
treatment at a single time-
point  
 
5 domains (24 items): 
 
Frequency of Complete Relief 
(FCR) (6 – how often complete 
 
 
 
 
 
 
Item stem and 
response options: 
1.’Static CORS’: 
categorical response 
options range  
3, 4 or 5-options: 
 
 
FCR: how often does 
your current M Rx 
‘overall 
experience with 
your current 
migraine 
treatment’ 
1.’Static CORS’: three 
domains scores based 
on item summation  
 
FCR (6): 
1a,2b,3b,4b,5b,6b 
SCR (6): 
1b,2c,3c,4c,5c,6c 
SRF (4): 7,8,9,10 
 
- where higher scores 
indicate better 
medication response 
 
2.’Comparative CORS’: 
item summation to 
10-15 minutes 
 
Not reported in 
headache 
population 
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relief of symptoms* plus 
irritability /moodiness**) 
 
 
Speed of Complete Relief (SCR)   
(6 - how quickly complete relief 
of symptoms* plus irritability/ 
moodiness**) 
 
 
Speed of Return to 
Functionality (SRF)(4 – able to 
concentrate/ think; normal 
activities; functioning normally 
(100%); feeling completely 
normal (100%)) 
 
Frequency of Migraine 
Recurrence (FMR)(1) 
 
Confidence in Treatment 
(CIT)(2) 
 
5 additional items describe 
presence of symptoms*: 
 
24-items address: 
Symptoms* - Headache-
specific pain; neck/shoulder 
pain; nausea; sensitivity to 
light; sensitivity to sound (5 
items). 
Emotional well-being – 
**irritability or moodiness 
Cognition – ability to 
‘concentrate or think’ 
ADL – resumption of normal 
activities 
Function – resumption of 
normal functioning (100%) 
Feeling ‘completely normal’ 
(100%) 
Confidence in current medical: 
frequency of return of M 
completely relieve 
your X?: 5-point (0-4): 
range 0= none of the 
time, to 4 = all or 
almost all of the time. 
 
SCR: how quickly does 
your current M Rx 
completely relieve 
your X?: 4-point (1-4): 
range 4 = < 30 mins, 
to 1 = > 2hrs 
 
SRF: how quickly are 
you able to … after 
taking your current M 
RX?: 5-point (1-5): 
range 5 = < 30 mins, 
to 1 = > 4hrs  
 
 
FMR: 5-point (0-4): 
range 0= none of the 
time, to 4 = all or 
almost all of the time. 
CIT: 3-point (0-2): 
range 0 = not at all 
confidence, 1 = 
somewhat confident; 
to 2 = very confident.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
produce index score 
(range 8 to 40), where 
higher scores suggest a 
better response to 
current medication 
than previous 
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within 24hrs; confidence that 
Rx will completely relieve M; 
confidence that M will not 
come back. 
 
 
2. ‘Comparative CORS (8 items) 
– for the comparative 
evaluation of two treatments 
at a single time-point. 
 
8 domains (8 items): 
Completeness of Relief (1) 
Speed of Relief (1) 
Persistence of Relief (1) (e.g. 
prevented symptoms from 
coming back within 24-hrs) 
Return to Normal Function (1) 
Fatigue (1) 
Confidence in Treatment (2): 
that one does would 
completely relieve M within 2-
hrs; that M would not come 
back within 24-hrs 
 
Overall Satisfaction (1) – most 
satisfied 
 
 
 
 
 
 
 
 
 
 
 
2. ‘Comparative 
CORS’: Which 
medication provided 
the complete / quicker 
/ longer-lasting / 
allowed more normal 
function / experience 
less fatigue / feel 
more confidence that 
one does would 
completely relieve 
your M within 2 
hours?: 
5-point categorical 
scale (1-5); where a 
score of ‘1’ favours 
the previous 
medication; a score of 
3 suggests no 
preference between 
medications; a score 
of 5 favours the study 
medication. 
Migraine – Assessment of Current Therapy  
 
(M-ACT) Copy included in publication 
 
(Dowson et al, 2004)[39] 
 
Self-completion 
 
2 4 domains (27 long-form/ 4 
short): 
Headache impact (11/1) 
Global assessment of relief 
(9/1) 
Consistency of response (3/1) 
Emotional response (4/1) 
 
 
Item stem: ‘When you 
take your treatment: 
Dichotomous 
answers: Yes/No, 
where Yes = 1 and No 
= 0 
Varies: between 
2hours and 48-
hours 
Item summation 
 
5-10 minutes 
 
Not reported in 
headache 
population 
Migraine Therapy Assessment Questionnaire 
 
(M-TAQ) 
1 To identify barriers to optimal 
migraine management and 
improve patient outcomes 
Dichotomous 
answers: Yes/No, 
Varies – mostly 2 
hours. 
Item summation 
Range 0 to 8 (items 3 
and 4 scored together), 
5-10 minutes 
 
30 
 
CHESS PROM review FTC: Appendices Edited 270717 
 
 
(Chatterton et al, 2002)[40] 
 
 
Self-completion 
Copy of PROM included in appendix to paper 
 
A disease-
management/screening tool to 
identify individuals whose 
migraine management is sub-
optimal (9) 
Migraine control, frequency of 
attacks, knowledge and 
behavioural barriers, economic 
burden, treatment satisfaction 
where Yes = 1 and No 
= 0 
where higher scores 
indicates greater 
number of migraine 
issues 
 
Also 3 domains:  
Migraine control; 
Knowledge/behaviour 
/treatment satisfaction; 
Economic burden,  
Not reported in 
headache 
population 
Migraine-Treatment Optimization Questionnaire 
 
(M-TOQ) 
 
(Lipton RB. et al. 2009) [41] 
 
Self-completion 
1 Aims to support treatment 
optimization – defined as the 
achievement of realistic 
treatment goals.  
 
The M-TOQ was developed to 
provide a rapid assessment of 
migraine therapy for use in 
primary care settings 
 
M-TOQ 15: 5 domains (15 
items): 
Functioning (3) 
Rapid relief of headache (3) 
Consistency of response (3) 
Prevention of recurrence (3) 
Side effects (3) 
 
M-TOQ 5: 5 domains (5 items) 
Functioning (1) 
Rapid relief of headache (1) 
Consistency of response (1) 
Prevention of recurrence (1) 
Side effects (1) 
 
Dichotomous 
answers: Yes/No, 
where Yes = 1 and No 
= 0 
Last 4 weeks M-TOQ 15 
Item summation 
producing five domain 
scores or an index 
score. High scores 
suggest good response 
to treatment, 
suggesting that 
treatment change is 
unlikely to be required. 
 
 
M-TOQ 5 
Item summation 
producing an index 
score. If answer ‘Yes’ to 
all five items - 
treatment is considered 
satisfactory. 
If answer ‘no’ to any 
single question, a 
change in treatment 
should be considered. 
 
A ‘treatment 
optimization’ table is 
provided to support 
score interpretation 
and clinical decision-
making (Table 5)[24] 
 
5-10 minutes 
 
Not reported in 
headache 
population 
Migraine Treatment Satisfaction Measure 
 
(MTSM)  
2 Migraine treatment 
satisfaction  
 
TE-M: 5-point 
response scale (1-5) 
where 1 is the worst 
At onset and 24 
hours after 
migraine episode 
Overall ‘MTSM’ 
treatment satisfaction 
score is generated as 
15-20 minutes 
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(Patrick et al, 2003) [42] 
 
Self-completion 
4-part assessment: 
1) Expectations of Treatment 
for Migraine (TE-M); 9 items) – 
worded to express the 9 
attributes as an ‘expectation’. 
2) Importance Ranking for 
Migraine Treatment (IR-M); 9 
items) – respondents rank 
items to express their ‘desired 
expectations; for each 
attribute.  
3) Outcomes of Treatment for 
Migraine (TO-M); 9-items – 
correspond to the TE-M items) 
– produces a self-report of 
treatment outcome for each 
attribute. 
4) Satisfaction with Migraine 
Treatment (PST-M; 9-items) – 
reflect satisfaction with 
treatment outcome across the 
9 attributes. 
 
9 attributes (‘items’) associated 
with migraine relief: 
Pain relief 
Speed of relief 
Freedom from pain 
Additional symptoms 
Confidence in treatment 
Disruption in life 
Dosing 
Freedom from relapse 
Ease of use 
 
case scenario (eg, no 
relief) and 5 is the 
best (eg total relief). 
 
IR-M: ranking items 
on a 10cm line (where 
0 = not important and 
10 = most important). 
Intersection with the 
line = score (range 0-
10). 
 
TO-M: 5-point 
response scale (1-5) 
reflecting actual 
outcome, where 1 =- 
worst case scenario 
(eg no relief) to 5 = 
best case (eg total 
relief). 
 
PST=M: 10cm VAS 
where 0 = most 
dissatisfied and 10 = 
most satisfied.  
 
 
the sum of the nine 
derived attribute scores 
(a detailed scoring 
procedure is detailed 
by the developers [27]): 
score represents 
patients expectations 
about Rx, modified by 
Rx experience, 
weighted by their 
adjusted importance 
values, and used to 
modify the raw 
satisfaction values [27].  
 
Scores also calculable 
for three domains:  
Expectations (TE-M) 
Outcomes (TO-M) 
Satisfaction (PST-M) 
 
Not reported in 
headache 
population 
Patient Perception of Migraine Questionnaire -Revised  
 
(PPMQ-R) 
 
(Revicki DA et al. 2006)[43] 
2 Patient satisfaction with acute 
migraine therapy 
 
Core: 4 domains (19 items) 
Efficacy: satisfaction with 
treatment efficacy (11) 
Function: ability to perform 
usual activities (4) 
Ease of Use (2) 
Core domains 1 to 4 
and 3 global items: 7-
point ‘Likert’ scale: 
range 1 = very 
satisfied to 7 = very 
dissatisfied.  
 
Domain 5 – 
‘Bothersomeness’: 5-
4 weeks Item summation to 
create domain scores: 
Domain 1: range 11 to 
77 
Domain 2: range 4 to 
28 
Domain 3: range 2 to 8 
Domain 4: range 2 to 8: 
where lower scores 
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Cost (2) (may be removed 
where ‘cost’ is not a 
consideration). 
 
Additional fifth domain (10 
items):  
‘Bothersomeness’ or 
‘Tolerability’ - related to side 
effects (10) 
 
 
3 global items: 
Overall satisfaction with 
medication effectiveness 
Side effects 
General treatment 
 
point ‘Likert’ scale: 
range 1 = not at all, to 
5 = extremely.  
 
 
suggest greater 
satisfaction with 
treatment. 
 
Item summation of 
three core domains 
(Efficacy, Function and 
Ease) to produce ‘Total 
Satisfaction Score’: 
score transformed to 0-
100, where higher 
scores represent 
greater satisfaction.  
 
 
 
       
Generic measures (6)     
Profile measures (3/6)     
Short Form 36-item Health Survey  
 
(SF-36) (version 1 (v1)) 
 
[Ware et al, 1994] [44] 
 
https://campaign.optum.com/content/optum/en/optum-
outcomes/what-we-do/health-surveys.html 
 
Self-completion or interview administered 
 General health status  
 
8 domains (36 items) 
Bodily pain (BP)(2) 
General health (GH)(5) 
Mental health (MH) (5)  
Physical functioning (PF)(10) 
Role limitation-emotional 
(RE)(3)  
Role limitation-physical (RP)(4)  
Social functioning (SF)(2)  
Vitality (V)(4) 
 
Categorical: 2-6 
options  
 
Recall:  
Standard 4-
weeks 
Acute 1-week 
Requires algorithm to 
score domains 
 
Norm-based scoring: 
score transformed to 0-
100 (mean 50 (SD 10))  
 
Individual domain 
scores (‘profile’) or  
2 summary scales: 
Physical Component 
Summary 
Mental Component 
Summary 
 
15 to 30 mins 
 
Not reported in 
headache 
population 
Short Form 12-item Health Survey  
 
(SF-12)(v1)  
 
[Ware et al, 1995][45] 
 
https://campaign.optum.com/content/optum/en/optum-
outcomes/what-we-do/health-surveys.html 
1 Health Status 
 
8 domains (12 items) 
Physical functioning ((n items 
per domains???) 
Social functioning 
Role physical 
Bodily pain 
Categorical: 2-6 
options  
 
Recall:  
Standard 4-
weeks 
Acute 1-week 
Requires algorithm to 
score domains 
 
Norm-based scoring: 
score transformed to 0-
100 (mean 50 (SD 10))  
 
2 summary scales: 
5-15 minutes 
 
Not reported in 
headache 
population 
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Self-completion or interview administered 
 
Mental health 
Role emotional 
Vitality 
General health 
 
Physical Component 
Summary 
Mental Component 
Summary 
 
Short Form 8-item Health Survey  
 
(SF-8)(v1)  
 
[Ware et al, 2001][46] 
 
https://campaign.optum.com/optum-outcomes/what-
we-do/health-
surveys.html?gclid=CPj1nb6YoM8CFXQo0wodZXEDLQ 
 
1 Health Status 
 
8 domains (8 items) 
Physical functioning (1) 
Social functioning (1) 
Role physical (1) 
Bodily pain (1) 
Mental health (1) 
Role emotional (1) 
Vitality (1) 
General health (1) 
Categorical: 2-6 
options  
 
Recall:  
Standard 4-
weeks 
Acute 1-week 
Requires algorithm to 
score domains 
 
Norm-based scoring: 
score transformed to 0-
100 (mean 50 (SD 10))  
 
2 summary scales: 
Physical Component 
Summary 
Mental Component 
Summary 
 
5-10 minutes 
 
Not reported in 
headache 
population 
       
Utility measures (3/6)       
EuroQoL EQ-5D (3L) 
 
(EuroQoL Group, 1990)[47]  
 
http://www.euroqol.org/ 
 
Self-completion or interview administered 
3 Quality of Life 
 
5 domains (5 items) 
Mobility 
Self-care 
Usual activities 
Pain/discomfort  
Anxiety/depression 
3-point descriptive 
response options: no 
problems, some 
problems, severe 
problems. 
Today Utility index value 
(society assigned value 
system algorithm): -
0.59 to 1.00 where 1.00 
is perfect quality of life, 
0 is death, and <0 is a 
health state worse than 
death 
2 to 5 mins 
 
Not  
reported in  
headache 
population 
 
       
Health Utility Index – 3  
 
(HUI-3) 
 
(Feeney et al, 2002)[48] 
 
http://www.healthutilities.com/hui3.htm 
 
Self-completion or interview administered 
1 Multi-attribute health status 
classification system 
 
Describes the comprehensive 
health state of an individual as 
8 domains (attributes) (8 
items):  
Vision 
Hearing 
Speech 
Ambulation 
Dexterity 
Emotion 
Cognition 
1 to 5 or 1 to 6 
descriptive response 
options per attribute / 
domain, where 1 is 
best health, 5 or 6 is 
worst health. 
Current Standard algorithms. 
0 to 1.00 where 1.00 is 
perfect QoL 
5 mins 
 
Not reported in 
headache 
population 
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Pain 
       
Quality of Well-being Scale  
 
(QWB) 
 
(QWB - Kaplan et al, 1993 [49]; QWB-SA - Andresen et al, 
1998 [50]) 
 
Interview and self-administered (SA) 
 
1 Generic measure of HRQoL; 
used to calculate QALYs 
 
QWB – interview administered 
(fewer than QWB-SA) 
QWB-SA – self-administered 
(77 items) 
 
Symptom scale 
3 scales of function: mobility, 
physical activity, social activity 
  
 
6-days 
3-days 
Overall score based on 
a preference-weighted 
average functioning in 
previous 6-days. 
 
Utility index score: 0.0 
(death) to 1.0 (perfect 
health) 
 
 
 
QWB-SA: 
average 11 
minutes 
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Appendix 5: Table 4: Characteristics of included studies (n= 46) 
Study 
(Author;yr) 
[ref] 
Countryg 
Languageg 
Population and 
Headache definition 
 
  
Study: design, setting, sample sizeg Mean gage 
(SD; range) 
Gender 
distribution 
(F Female)g 
Treatment descriptionsg % missing 
responses: 
acceptable?g * 
PROM focus; 
Additional info g 
Andree et 
al 2010 
[28] 
Five countries: UK, 
Italy, Spain, 
Germany/Austria, 
France 
Patients from mixed 
settings with 
diagnosis of 
headache: 
International 
Classification of 
Headache Disorders 
(ICHD-II) 2004 
 
 
 
International cross-sectional survey:  
 
Population recruitment: 
UK and Italy: Headache/migraine associations; 
France/ Austria/ Italy: Neuroscience clinics;  
Germany/ Luxembourg: population based 
cohort; 
Spain: GP population 
 
Total n=426 
UK n=131 
Italy n= 60 
Spain n=107 
Germany/Austria n= 83 
France n=45 
 
Total: 
44.0 (+/- 
11.38) 
Total: 
F 75.0% 
NA Total: quoted as 
66-100% (data 
NR) not quoted 
at item level 
EUROLITE - 
development 
Bagley et al 
2012 [54] 
Data from 9 
countries: US, 
Canada, France, 
Germany, Spain, 
UK, Australia, Italy, 
Taiwan. 
 
Chronic (CM) and 
Episodic Migraine 
(EM) 
 
Detailed definitions 
(p410) 
International Burden of Migraine Study (IBMS) 
 
Web-based, cross-sectional population survey 
 
Participants recruited from established 
database of headache / migraine patients (n 
Total:  
40.3 (11.4) 
 
EM 40.2 
(11.4) 
Total:  
F 83.5% 
 
EM F 83.4% 
 
N/A 
 
 
Not reported at 
item level 
MSQ 2.1 
 
Includes a ‘review’ 
of the 
development / 
earlier evaluation 
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Suggests that 
questionnaires 
completed in 
‘official language 
of the country’ – 
but results then 
combined 
 
EM: <15 HDPM 
CM: >/= 15 HDPM 
 
63,001): all received e-invitation to ‘opt in’ via 
web-link.  
30.7% responded to email invitation; 55% 
eligible to participate.  
 
Surveys completed by 81.9% 
Total n 8726 
 
EM n 8227 
CM n 499 
 
 
CM 41.7 
(12.1) 
CM F 85.6% papers for MSQ 
and HIT-6. 
Bigal et al 
2003 [69] 
US 
 
US English 
Patients registered 
with a specialist 
headache clinic 
 
CM: daily or near-
daily headaches 
lasting >4hrs if 
untreated, >15 days 
per month, fulfilling 
CDH. 
 
EM: HIS for migraine 
+/- aura 
Retrospective assessment of patient clinic notes 
(for those who had previously completed the 
MIDAS) 
 
CM 182 
EM 86 
 
 
CM 38.3 
(95% CI 
36.5 to 
40.1)  
 
EM 36.1 
(95% CI 
34.1 to 
38.0) 
CM F 72.5% 
 
EM F 68.6% 
N/A Not reported at 
group or item 
level 
MIDAS 
 
Bjorner et 
al 2003a [3]      
 
US 
 
US English 
General population 
 
At least 1 headache in 
4/52 prior to 
interview (not 
hangover, cold, flu) 
 
National Survey of Headache Impact (NSHI) – 
longitudinal survey (baseline and 3/12) 
 
Sampling frame: randomly generated list of 
telephone numbers from 48 US states. 
 
NR 
 
Reported 
elsewhere 
in NSHI 
papers 
NR N/A  
N/A 
HIT development 
paper  
 
Focus: item pool 
development. 
Informed by items 
from the: MSQ 
(v2), HDI, HIMQ, 
MIDAS 
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 Interviews with convenience sample of eligible 
respondents (mean duration 21.5mins (rge 17-
27 mins) – schedule not detailed 
 
Telephone interviews n= 1016 
 
Headache prevalence in 4/52 period= 45.7% 
 
Blumenfeld 
et al 2010 
[71] 
Data from 9 
countries: US, 
Canada, France, 
Germany, Spain, 
UK, Australia, Italy, 
Taiwan. 
 
 
Suggests that 
questionnaires 
completed in 
‘official language 
of the country’ – 
but results then 
combined 
Chronic (CM) and 
Episodic Migraine 
(EM) 
 
Detailed definitions 
(p410) 
 
EM: <15 HDPM 
CM: >/= 15 HDPM 
 
International Burden of Migraine Study (IBMS) 
 
Web-based, cross-sectional population survey 
 
Participants recruited from established 
database of headache / migraine patients (n 
63,001): all received e-invitation to ‘opt in’ via 
web-link.  
30.7% responded to email invitation; 55% 
eligible to participate.  
 
Surveys completed by 81.9% 
Total n 8726 
 
EM n 8227 
CM n 499 
Total:  
40.3 (11.4) 
 
EM 40.2 
(11.4) 
 
CM 41.7 
(12.1) 
Total:  
F 83.5% 
 
EM F 83.4% 
 
CM F 85.6% 
N/A 
 
 
Not reported at 
item level 
MIDAS 
 
* Sub-division of 
Grade IV into IV-A 
severe disability 
(score 21-40) and 
IV-B very severe 
disability (41-270): 
reflects number of 
people with CM 
who fall into the 
grade IV category. 
(ceiling effect – 
worst scores)  
 
Includes a ‘review’ 
of the 
development / 
earlier evaluation 
papers for MSQ 
and HIT-6. 
 
 
Brown et al 
2005 [79] 
US 
 
Care-seeking patients 
for migraine 
headache - registered 
at three sites 
representing varied 
Cross-sectional survey questionnaire – primary 
focus evaluation of the HUI-3 in this population 
 
44.0 (11.6) F 87% 
 
N/A Not reported. HUI-3 
(MIDAS) 
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US English models of healthcare: 
primary care 
speciality clinic, non-
profit HMO. 
 
EM: physician 
diagnosed at least 1-
year before study 
enrolment (medical 
chart review) 
Consecutive patients recruited (each site total 
n50).  
 
N 150 
(Causasian 
87%) 
 
Mean HUI-3 scpre 
0.62 (SD0.26) 
Chatterton 
et al 2002 
[40] 
US  
 
US English 
 
Migraine diagnosis At 
least 1 migraine per 
month and 
Cross-sectional survey questionnaire - primary 
focus evaluation of the M-TAQ; two-week test-
retest (of individual items) on sub-set (n 100) 
 
N 243 
 
40.0 
Range 18-
63 
F n 219 
(91%) 
 
(Caucasian 
63%) 
N/A Not reported. M-TAQ – 
development 
paper 
 
(SF-36, MIDAS, 
Beck Depression 
Inventory) 
 
Test-retest at 2-
weeks (n 100) 
 
Coeytaux 
et al 2006 
[58] 
US 
 
US English 
Specialist headache 
clinic 
 
Chronic Daily 
Headache (CDH): 
presence of headache 
on >/= 15 days in the 
month prior to 
enrolling in clinical 
trial 
 
Total recruited with 
CDH n 71 
Randomized clinical trial: Usual medical care 
(UMC) (n37) v UMC plus acupuncture (n34)  
 
Questionnaires administered at baseline and 
6/52. Include patient self-report of meaningful 
improvement/no change/ deterioration at 6/52. 
 
 
Mean 46.0; 
range 19-83 
yrs. 
F 80% (n 
57) 
 
(93% white 
(n 66)) 
 
Usual medical care (UMC) 
(n37) v UMC plus 
acupuncture (n34) 
(consisting of 10 treatments 
over 6-wks) 
Complete follow-
up data for 
71/74 enrolled 
patients (96%) 
HIT-6 
 
Patient-reported 
change in status at 
6/52: 42% 
improved; 44% no 
change; 14% 
worse 
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Mean duration of 
CDH 24.2 (SD 5.8) 
days 
 
 
 
Cole et al 
2009 [60] 
 
US and Canada 
 
US English 
1.Participants in 
clinical trial; and 2. 
Members of the 
general population 
 
EM or Self-report 
Headache:  
 
EM: minimum 6-mth 
history of Migraine 
(HIS criteria) with 3-
12 Migraines per mth 
but not >15 HDPM 
during the 28-day 
prospective baseline 
period. 
 
Self-report headache 
at least once in past 
4-weeks (prior to 
phone interview) 
 
 
Retrospective data analysis of two data-sets: 
 
1. Pooled data from 2 randomized clinical trials 
(RCTs) (n 916) (Topiramite for Migraine 
prevention) 
 
2. Population-based database (n 1016) 
1. rge 12-65 
yrs 
 
2. rge 18-65 
yrs 
 
Additional 
data NR 
NR 1. Double-blind placebo-
controlled RCT 
 
2. No intervention 
Missing data: 
handling detailed 
p1181 (Bayesian 
multivariate 
imputation 
method) 
MSQ v2.1 
 
Focus on MID 
calculation for 
MSQ v2.1 (anchor 
and distribution 
based analysis) 
(p1182) 
Cole et al 
2007 [51] 
US and Canada 
 
US English 
Participants in a 
clinical trial 
 
Retrospective data analysis: pooled data from 2 
randomized clinical trials (RCTs) (n 916) 
(Topiramite for Migraine prevention) 
40.7 (10.7) 
 
NR  Double-blind placebo-
controlled RCT - 
Prophylactic migraine 
treatment 
Missing data 
detailed. 
MSQ 
v2.1: Baseline: 
MSQ v2.1 
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6-mth history of 
Migraine (IHS criteria) 
with 3-12 Migraines 
per mth but not >15 
HDPM during the 28-
day prospective 
baseline period.  
 
 
 
 
 
MSQ v2.1 completed baseline, 2/4/6mths 
 
 
 range 0% 
(several items) to 
0.44% (items 3 
and 4) 
 
 
Reports results for 
both 14-item 
(v2.1) and a 
revised 13-item 
measure 
(informed by 
results of initial 
testing) 
 
IRT evaluation 
 
Coon et al  
2012 [38] 
US 
 
US English 
 
Patients registered 
with specialist 
headache clinics (8 
sites) 
 
IHS diagnosis of 
migraine +/- aura for 
at least 1 year based 
on medical, 
medication and 
migraine history. 
During 3-mths prior to 
study enrolment – 
required to have x 3 
to 8 migraine attacks 
per month and to 
have used triptans at 
least x2 per month. 
 
 
Clinical study (before / after) (sumatriptan and 
naproxen versus usual therapy) 
 
n 916 
 
Baseline (BL) static CORS completed to reflect 
experience of ‘usual therapy’.  
 
After 2-mths treatment with Suma/Nap they 
completed the  EOS static CORS (re-phrased to 
focus on Suma/Nap); comparative CORS also 
completed.   
 
44.3 (11.0); 
range 19-
65yrs 
F 87.1%  
 
(91.2% 
white) 
Visit 1 (for 2-mths): 
participants treated any 
migraine with single-tablet 
formulation of Suma/Nap. 
 
 
Not reported (at 
survey level) 
Focus: treatment-
specific measure -  
CORS 
 
Mean 22.4yrs 
(13.2; range 1-53) 
since Migraine 
onset) 
 
Average HIT-6 at 
baseline 61.7 
(range 42-76) 
suggesting severe 
impact of 
headache 
 
Cramer et 
al 2001 
[34] 
US 
 
US English 
 
Patients with history 
of migraine.  
 
Migraine not defined.  
Development and initial evaluation of the 
HANA: data from three studies: 
 
1.Mean NR. 
Range 19-
>65 
 
1. F 
804/994 
(81%) 
2. F 17/28 
(61%) 
1. N/A 
2. Migraine prophylaxis 
clinical trial 
2. Usual care 
‘No floor or 
ceiling effects’ 
reported (but 
data not 
illustrated) 
HANA - 
development 
paper 
(HDI) 
41 
 
CHESS PROM review FTC: Appendices Edited 270717 
 
1.Participants in the Life Impact Survey – a web-
based survey (supported and widely publicised 
by various Headache and Migraine groups) 
N 994 
 
2.Participants in a migraine prophylaxis clinical 
trial. 
N 28 
 
3. 1-month test-retest cohort: ‘no change in 
status’ (anchor not reported) 
N 25 
 
2. 40.7 
(11.1); 
range 16-69 
 
3. 44.0; 
range 16-62 
3. F 21/25 
(84%) 
Davis et al 
2002 [76] 
Data from 6 
countries: Spain, 
NZ, NL, Hungary, 
Finland, Canada 
Clinical trial 
participants 
 
Diagnosed according 
to IHS criteria 
 
N 793 
Multinational, open-label trial (oral naratriptan) 
vs ‘usual therapy for M’. Duration 3-months 
 
Baseline and 3-mths completion (end of trial) 
Total 
population 
38.4  
 
Country 
mean age 
range: 
Spain 36.2 
(9.1) to 
Canada  
40.2 (8.7)  
 
F 85%  
 
(98% white) 
  PPMQ (original 
version)  
 
Limited detail re 
PPMQ 
development ( 
 
 
Dodick et al 
2007 [61] 
US 
 
US English 
Patients aged >18 
years with chronic 
migraine 
 
Migraine deﬁned 
according ICHD-II, 
with duration of 30 
minutes or longer. 
RCT – patients randomized 1 : 1 ratio to 
topiramate 100 mg/day or placebo (double-
blind period 16weeks) 
 
n328 
38.2 F 85.3% N/A 
 
Report responsiveness 
(correlation of change 
scores) 
Calculate MID (within-
person (MIC)) for MSQv2.1 
NR MIDAS 
MSQ v2.1 
Subjective Global 
impression of 
change (SGIC) 
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CM identiﬁed based 
on Silberstein–Lipton 
criteria, which 
required the presence 
of at least 15 
headache days during 
the 28-day 
prospective baseline 
period 
 
SGIC completed at the end 
of the study – 7-point scale 
(1= very much improved to 
7= very much worse) 
Physician GIC also 
completed. 
 
Dowson et 
al 2004 
[39] 
International 
study: 5 counties: 
UK, US, Spain, 
Germany, Italy.  
 
All questionnaires 
translated into 
local language. 
Patients registered at 
secondary care 
headache centres and 
attending for 
migraine treatment. 
 
Migraine diagnosed 
according to IHS 
criteria (1998; 2004): 
participants aged 18-
65yrs; minimum 1 yr 
history of migraine; 
average 1-4 attacks 
per month and 
minimum 24-hrs 
between attacks, and 
able to distinguish 
migraine from other 
headache.  
 
Development and initial evaluation of the M-
ACT: Open, prospective, multi-national, 
observational, two-visit study. 
 
Baseline (n 185)  
1-week test-retest (n 143) (no change in 
treatment during this time; but no health 
transition question reported).  
Questionnaire completed in clinic or by 
telephone.  
44.0; range 
14-87 (93% 
aged 18-65) 
F 68% 
 
(Caucasian 
99.4%) 
N/A NR M-ACT – 
development 
paper 
(SF-36, MIDAS, M-
TAQ) 
Gillard et al 
2012 [73] 
Data from 9 
countries: US, 
Canada, France, 
Germany, Spain, 
UK, Australia, Italy, 
Taiwan. 
 
 
Episodic and chronic 
M 
 
Migraine defined 
according to 
International 
Classification of 
Headache Disorders 
(2nd Edition): plus 
International Burden of Migraine Study (IBMS) 
 
Cross-sectional, web-based observation study: 
paired observations of participants 
 
Individuals randomly assigned to training or 
‘validation’ samples 
NR in this 
paper for 
total pop. 
Presented 
by MSQ and 
HIT-6 
completion  
(Table 1 
p486) 
Range 83-
86% female 
N/A NR  – assumed 
how dealt with?? 
EQ-5D with HIT-6 
and MSQv2.1 
 
Conclusion: 
relationship 
between the EQ-
5D and both 
measures is 
adequate to use 
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Suggests that 
questionnaires 
completed in 
‘official language 
of the country’ – 
but results then 
combined 
Chronic >/= 15 days 
per month; Episodic 
(< 15 HD per mth) 
 
Total > 8500 
CM >450 
EM >8000 
 
Aim: to develop empirical algorithms to 
estimate health state utility values from 
disease-specific QOL scores in individuals with 
migraine 
 
Range 
(Median) 
39-42 yrs 
(range 18-
85) 
regressions 
equations to 
estimate EQ-5D 
utility values. The 
preferred HIT-6 
and MSQ 
algorithms can be 
used to estimate 
HSU in trials where 
a preference 
based measure is 
not used. 
Kawata et 
al 2005 
[55] 
US 
 
US English 
New adult patients at 
university headache-
speciality practice 
 
Diagnosis not 
specified 
Cross-sectional survey   
 
All new patients who presented at clinic from 
Jan-Sept 2001 
 
N 309 
 
41.0 (SD 13) 
 
Range 18-
91 yrs. 
 
F 77% NR Questionnaire 
response rate 
309/369 (84%). 
HIT completion 
not reported at 
item level 
HIT 
Kilinster et 
al 2006 
[74] 
International 
study: 5 counties: 
UK, US, Spain, 
Germany, Italy.  
 
All questionnaires 
translated into 
local language. 
Patients registered at 
secondary care 
headache centres and 
attending for 
migraine treatment. 
 
Migraine diagnosed 
according to IHS 
criteria (1998; 2004): 
participants aged 18-
65yrs; minimum 1 yr 
history of migraine; 
average 1-4 attacks 
per month and 
minimum 24-hrs 
between attacks, and 
able to distinguish 
migraine from other 
headache.  
Secondary analysis of data from the M-ACT 
study database (Dowson et al, 2000): evaluation 
of M-ACT reliability and validity. 
 
Open, prospective, multi-national, 
observational, two-visit study. Data analysed for 
total population and per country 
 
Baseline (n 185)  
1-week test-retest (n 143) Questionnaire 
completed in clinic or by telephone. 
44.0; range 
14-87 (93% 
aged 18-65) 
F 68% 
 
(Caucasian 
99.4%) 
N/A NR M-ACT  
(SF-36, MIDAS, M-
TAQ) 
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Kimel et al 
2008 [75] 
US 
 
US English 
Minimum 6/12 
history that met HIS 
criteria for Migraine 
with aura; 
experienced 2-6 
Migraines per mth in 
the 3mths prior to 
screening (screening 
assessment to 
confirm diagnosis) 
 
Data from two identical phase 3 trials: fixed 
dose sumatriptan + naproxen sodium Vs 
placebo 
 
N 1304 
40.1 (11.09) F 87.8%  Fixed dose sumatriptan + 
naproxen sodium Vs 
placebo 
 
Detailed p514-
515 
PPMQ-R 
 
Evaluate 
psychometric 
properties in 
clinical trial setting 
  
Kosinski et 
al 2003 
[31] 
US 
 
US English 
Members of the 
general population 
with experience of 
recent headache (self-
diagnosed?) 
 
A headache in the last 
4-weeks that was not 
due to cold, flu, head 
injury, hangover 
 
Two on-line community-based surveys (platform 
AOL’s Opinion Place). 
 
Time 1: n 1103 
Time 2: n 540 
 
Time 1. 
37.0  
 
Time 2. 
37.5 
Time 1:                 
F 73%  
 
Time 2:                
F 72%  
N/A 
 
 (HIT and) HIT-6 
development 
paper 
Lipton et al 
2003 [77] 
US and UK 
 
US / UK English 
Migraine (n 399) and 
non-migraine (n 379) 
controls (data pooled 
for both populations 
p631) 
 
HIS defined migraine 
(computer-assisted 
telephone interview 
(CATI)): HIS migraine 
+/- aura: 6 or more M 
in last year, but 15 or 
< headaches (any 
type) in previous 
month. 
Two population-based studies (UK and US) – 
cross-sectional survey. Evaluation of migraine, 
quality of life (SF-12) and depression: patients 
with migraine versus non-migraine 
counterparts. 
NR in this 
article – 
web-link 
provided. 
NR Nil. NR SF-12 
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Lipton et al  
2009 [41] 
6 countries: 
Canada, France, 
Germany, Italy, 
Spain, USA 
Community-based 
population 
 
IHS for Migraine +/- 
aura; at least x1 M 
per mth in the past 
3mths; and no change 
in Rx for M in past 
3mths.  
 
Focus to establish the reliability and validity of a 
new measure – the M-TOQ: evaluation in five 
languages. 
 
25 Primary care centres: N 253 (n50 per 
language) 
 
Questionnaire completion during clinic-based 
interview: package of measures including M-
TOQ, MIDAS, HIT-6, MSQoL. (Unclear if all pen 
and paper or some touch-screen completion). 
 
Test-retest completion at 7-10 days (pen and 
paper completion). 
 
 
43.1 (12.4) F 90.1% 
  
N/A 
 
Evaluation of: data quality 
(missing values not 
reported), structural 
validity, internal 
consistency reliability, item-
total correlation, 
convergent validity. 
NR M-TOQ 
 
(HIT-6, MSQoL) 
Lipton et al 
2016 [59] 
US 
 
US English 
 
Eligible adults (aged 
18–65 years) - 
International 
Classiﬁcation of 
Headache Disorders 
(ICHD-2) diagnostic 
criteria for CM .  
 
To be eligible for 
inclusion, patients 
must have had >15 
headache days during 
the 28-day screening 
period (baseline), 
during which >4 hours 
of each headache day 
were continuous 
headache and >50% 
were migraine or 
Patients with CM from PREEMPT (Phase 3 
REsearch Evaluating Migraine Prophylaxis 
Therapy) were randomized (1:1) to receive 
onabotulinumtoxinA or placebo for two 12-
week cycles in the double-blind (DB) phase, 
followed by three 12-week cycles of open-label 
(OL) onabotulinumtoxinA 
(onabotulinumtoxinA/onabotulinumtoxinA 
(O/O) and placebo/onabotulinumtoxinA (P/O) 
groups, respectively).  
 
n1236 participants (O/O, n607; P/O, n629) 
participated in both phases 
 
HRQoL endpoints were assessed over 56 weeks 
using the HIT-6 and MSQv2.1 
Baseline 41 
(SD 10) yrs 
 
White 90% 
F 85% PREEMPT clinical trial 
 
Focus of report – the 
pooled HRQOL outcomes 
for 56-week treatment 
period. 
 
Baseline 
Mean HIT-6 65.4 (4.2) 
Mean MSQ: 
  RR 38.6 
  RP 56.0 
  EF 42.2 
Missing HIT-6 
data were 
imputed using a 
prespeciﬁed, 
modiﬁed last 
observation 
carried forward 
technique (6,7). 
All observed 
MSQ data were 
analyzed without 
imputation for 
missing values. 
HIT-6 
  36-49 no impact 
  55-55 substantial 
impact 
  60-78 severe 
impact 
 
MSQv2.1 
  Range 0 (poor) to 
100 (goodHRQoL) 
 
Paper describes 
where the 
measures have 
exceeded 
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probable migraine 
days.  
 
Mean duration since 
CM onset 19yrs 
 
  
At baseline most patients 
were severely debilitated 
by their migraines: 93% 
reporting a total HIT-6 score 
>60 (severe impact) and 
another 5% reporting a 
score of 56–59 (substantial 
impact)  
proposed MIC or 
MID 
Magnusson 
et al 2012 
[32] 
Canada 
 
US English 
Pre-IHS definition for 
chronic migraine; 
patients fulfilled 
criteria for 
transformed migraine 
+/- medication 
overuse 
 
All patients were 
diagnosed with 
Migraine and had 
headache on >15 days 
per mth (fulfilling IHS 
criteria) 
Patient registered with specialist headache 
centre studies: 
 
1) Canadian Headache Outpatient Registry and 
Database (CHORD) (n 83);    
 
2) Calgary Specialist headache clinic study (n 76) 
 
Groups had similar demographics, number of H 
days and amount of H-related disability 
 
1)41.0 
 
2) 41.2 
1) 
F n64;   
M n19 
 
2)  
F n64;  
M n12 
N/A 
 
 
N/R SF-36 Headache 
Modification (SF-
36, HIT-6) 
 
 
Group 1 
completed the SF-
36 Headache 
Modification; 
Group 2 the 
original SF-36 (v1) 
 
 
 
 
Martin et al  
2000 [36] 
US  
 
US English 
Patients attending 4 
outpatient headache 
speciality clinics  
 
Diagnosed according 
to  
IHS criteria 
 
 
Multicenter, nondrug, prospective, parallel 
group, quasi-experimental design. 
 
N= 267 
(157 new and 110 stable) 
New 
patients: 
39.0 
 
Stable 
patients: 
44.6 
F 90.6% Stable patients: TAU 
 
New patients:  acute or 
prophylactic medications  
recommended by headache 
specialist 
Item level: no 
missing 
observations or 
out of range 
values for either 
group 
MSQ v2.1 
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Martin et al 
2008 [65] 
US 
US English 
Sub-set of 
participants with CH 
in a large multi-site 
RCT.  
 
RCT inclusion: >21 yrs 
old; MIDAS score >5; 
intending to continue 
with general medical 
care; CH diagnosis 
defined below: 
 
CH: tension-type, 
migraine or mixed 
aetiology. 
Diagnosed by primary 
care physician 
(frequent and/or 
difficult to manage 
headaches) 
Secondary analysis of RCT data: Headache 
Management Progammes (HMP): aimed at 
reducing H-related disability, improving process 
of care, reducing management costs. 
 
Total n 124 
 
Primary focus: MTSM evaluation in a sub-set of 
RCT population; Baseline (parts 1 and 2) and 6-
mths (parts 3 and 4): self-completion (mail) 
 
45.4 (11.6) F 75%  
 
(59.7% 
Caucasian) 
 
N/A 
 
NR MTSM 
(SF-36, MIDAS) 
 
 
 
McKenna 
et al 1998 
[37] 
UK and US 
 
UK and US English 
 
Part of 
international study 
conducted in 8 
countries. 
 
Patients with history 
of migraine. 
 
UK: Migraine 
diagnosed by clinician 
US: Migraine 
diagnosed by clinical 
specialist 
 
No further definition 
provided.  
Development and initial evaluation of UK 
version. 
1.Qualitative: interviews (UK n 30; US n25) and 
focus groups (US).   
Recruitment: UK from general practice, British 
Migraine Association, pharma company 
employees. 
US: from specialist clinics. 
 
2. Postal survey (UK): Baseline n 87/90 
completed questionnaire; 2-week test-retest 
questionnaire n87/87. 
1. NR 
 
2. 47.6; 
range 22-92 
 
1.NR 
 
2. F n72 
(83%) 
NA NR MSQoL – 
development 
paper 
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Niere & 
Quin 2009 
[30] 
Australia 
 
Australian English 
Patients attending 
private practice out-
patient physiotherapy 
clinics (n45) for 
headache 
management 
 
IHS diagnostic criteria 
(1988) for Migraine 
+/- aura, Migraine 
with aura and tension 
type headache. 
Diagnostic   criteria 
for   cervicogenic 
headache.  
 
Cross-sectional evaluation of the HDQ  
 
Clinicians’ selected consecutive patients 
meeting inclusion criteria 
 
N 111 
38.3 (12.2)  
Range 18.0-
74.0   
F n93 
(83.8%)  
 
 
NA Item response 
rates: 95%-100% 
(14 of 16 items 
at least 98%) 
HDQ – 
development 
paper 
Patrick et al 
2000 [52] 
8 countries: US, 
UK, France, 
Denmark, 
Germany, Italy, 
Spain, Sweden. 
Previous participants 
in placebo-controlled 
trial: recruited into 
long-term 
observational study. 
Registered with 
specialist headache 
clinics.  
 
IHS – diagnosed with 
Migraine  
Non-comparative long-term observational study 
of zolmitriptan (Zomig) for acute treatment of 
migraine attack of any intensity (over 12-mths) 
 
 
 
N 1383 
 
41.2 
(10.01); 
range 12-66 
1190 F; 193 
M (86:14) 
 
Caucasian: 
96.5% 
 
 
 
 Focus: MSQoL (20-
item) 
(Also SF-36 (US 
only; n= 1115).  
 
Questionnaires 
completed: after 
treating 1, 5 and 
17 M attacks or at 
3-mthly intervals  
Patrick et al 
2003 [42] 
US and UK English Development and 
initial evaluation of 
new measure (MTSM) 
Participants identified 
by their referring 
clinician as “a 
migraine patient 
starting a new 
treatment.” 
1.Participants in initial interviews / focus groups 
– item generation (US (30); UK (24)) and 
confirmation (23); Headache experts (US 3; UK 
1). No additional detail. 
 
2.Participants in clinic-based study (n=29) – to 
test the feasibility of using the MTSM in a 
clinical setting and to generate a preliminary 
data set from small group of patients. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
New migraine treatment. 
 
22 (75.9%) started on a 
triptan (ie, sumatriptan, 
naratriptan, rizatriptan, 
zolmitriptan, or 
almotriptan); 12/22 (54.5%) 
were already receiving a 
triptan, and the other 10 
NR Development and 
initial evaluation 
of the MTSM 
 
Questionnaire 
completed 
baseline and 
follow-up. 
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42.0 (11.3); 
range 24-64 
 
28 F (97%) 
 
Caucasian 
25 (86%) 
(45.5%) were receiving an 
analgesic.  
Remaining 7 (24.1%) were 
changing migraine drugs; of 
these, 2 participants had 
been receiving a triptan: 1 
was now starting an 
analgesic (naproxen) and 1 
was starting an 
antidepressant 
(citalopram).  
The 4 participants who 
were originally taking an 
analgesic started a new 
analgesic (naproxen or 
butalbital).  
The remaining participant 
had been receiving an 
anxiolytic (alprazolam) and 
was now starting 
paroxetine (an 
antidepressant/anxiolytic 
also used for headaches). 
 
Initial evidence for 
validity assessed 
against 24-hr 
MQoLQ and SF-36. 
Pathak et al 
2005 [33] 
 
US and Germany 
 
Migraine (IHS): at 
least 3 migraines in 
previous 12mths. 
Stages in the development of the FAIM – a new 
measure. 
1) Focus groups in US and German – 
limited detail 
2) Pre-testing – item evaluation and 
reduction: n153 US and n148 
Germany 
3) Pilot test and final item reduction: 
n75 US and n83 Germany 
  
Study 2: US 
37.5 (13.2) 
G 43.3 
(13.7) 
 
Study 3: US 
38.8 (11.2) 
G 41.0 
(13.5) 
F 
Study 2: 
US 66.2% 
G 71.5% 
 
Study 3: 
US 76.8 % 
G 69.9% 
Stages in PROM 
development. No 
treatment. 
Detailed per 
stage of 
developmet 
Development of 
the FAIM 
Rendas-
Baum et al 
2013 [12] 
US, Canada, UK, 
Croatia, Germany 
and Switzerland. 
International trial 
participants with 
diagnosis of migraine:  
Secondary analysis of data from two multicentre 
double blind placebo controlled RCTs of chronic 
migraine patients receiving BOTOX as 
prophylaxis 
Study 1: 
41.6 (10.5) 
Trial 1: 
F 87.5% 
 Not reported Comparative 
evaluation of the 
MSQ v2.1 and HIT-
6 
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 ICHD-II for migraine, 
with the exception of 
“complicated 
migraine” 
≥15 headache days 
during 4-week 
baseline phase; each 
headache day of ≥4 
hours of continuous 
headache; 
≥50% of baseline 
headache days 
migraine/probable 
migraine days. 
 
 
Total N 1376 
Trial 1: n 672 
Trial 2: n 704 
 
Study 2: 
41.0 (10.6) 
 
Trial 2: 
 F 85.4%  
Rendas-
Baum et al 
2014 [53] 
US, Canada, UK, 
Croatia, Germany 
and Switzerland. 
 
International trial 
participants with 
diagnosis of migraine:  
ICHD-II for migraine, 
with the exception of 
“complicated 
migraine” 
≥15 headache days 
during 4-week 
baseline phase; each 
headache day of ≥4 
hours of continuous 
headache; 
≥50% of baseline 
headache days 
migraine/probable 
migraine days. 
 
Secondary analysis of data from two multicentre 
double blind placebo controlled RCTs of chronic 
migraine patients receiving BOTOX as 
prophylaxis 
 
Total N 1376 
Trial 1: n 672 
Trial 2: n 704 
Study 1: 
41.6 (10.5) 
 
Study 2: 
41.0 (10.6) 
Trial 1: 
F 87.5% 
 
Trial 2: 
 F 85.4%  
 Not reported Comparative 
evaluation of the 
HIT-6 and MSQ 
v2.1 
Revicki et 
al 2006 
[43] 
US 
 
US English 
Primary Care and 
neurology speciality 
clinics (n=50) 
 
Longitudinal observational study: patients 
receive usual medical care; study investigators 
had discretion to change or prescribe 
medications  
39.0 (11.0) F n 181 
(91%) 
 
 Detailed Table 3 
(p 246) 
 
PPMQ-R 
Development / 
revision paper  
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Documented 
diagnosis of migraine 
+/- aura (1988 IHS 
criteria 1.1 and 1.2): 2 
to 8 Migraine attacks 
per month for at least 
3-mths prior to study 
enrolment. 
 
Able to distinguish 
Migraine from other 
Headache 
 
 
N 200  
Convenience sampling from participating clinics 
(not detailed) 
(Caucasian 
n 63 (82%)) 
Ceiling effects 
for all 10 
Bothersome 
items (>50%) and 
two ease of use 
items. 
 
Participants kept a 
Migriane diary and 
completed the 
draft PPMQ-R at 
24-hrs post-Rx for 
each M attack 
 
(MSQv2.1) 
Sauro et al 
2010 [70] 
Canada 
 
Canadian English 
Patients registered 
with Neurology 
Outpatient practices - 
patients referred by 
family physician or 
other specialist 
 
Patients diagnosed 
according to IHS 
criteria - except 
patients with chronic 
daily headache 
(headache on 15 days 
a month or more). 
 
Cross-sectional evaluation 
 
Patients identified from the Canadian Headache 
Outpatient Registry and Database (CHORD) – 
patients registered with five neurology 
outpatient practices (Sept 2001-Jan 2004) 
 
N 798 
40.3 (SD 
13.7) 
F 77% NR Response rate 
92% 
 
Item level: only 
those with ‘valid 
scores’ included 
in the analysis. 
HIT-6 
Sieber et al 
2000 [64] 
 
Canada 
 
Canadian English 
n89 adults ‘known to 
suffer with migraine’ 
Cross-sectional, comparative evaluation of QWB 
and QWB-SA for patients with migraine. 
 
Postal self-completion of QWB-SA 
Telephone-administered completion of QWB 
42.2 (9.8) 
Range 36 to 
64yrs 
F 87% Questionnaires completed 
at 3-points: first, on a day 
when migraine had not 
been experienced within 
previous 7-days; 2nd and 3rd 
within 48hrs of onset of 
migraine. 
Not reported. 
 
Greater number 
of completions 
of QWB than 
QWB-SA 
 
QWB (interview) 
QWB-SA (self-
administered) 
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Stafford et 
al 2012 
[72] 
UK 
 
English 
Members of the 
general population 
who had recently 
experienced a 
Migraine:  
IHS definition: 
Migraine +/- aura.  
At least 1 Migraine in 
the last 7 days and 
history of physician 
diagnosed Migraine 
for at least 6mths. 
 
 
 
Cross-sectional observational study. 
 
Recruited via Migraine support groups and 
support group databases – eligibility confirmed 
via telephone interview. Aged >18yrs. 
 
N 105 
 
Mean number of monthly Migraines 5.22 (4.1); 
range 1 to 20. 
 
MIDAS grade: iv 51/106 
Iii 32/106 
Ii 14/106 
I 9/106 
47.45 
(11.71)  
F n 81 
(76.4%) 
 
(Caucasian 
n 89 
(83.2%)) 
 Missing items 
dealt with as 
recommended 
by EQ-5D 
developers 
 
1 patient did not 
complete EQ-5D 
for current 
health status – 
therefore 
numbers 
reduced from 
106 to 105 
 
 
EQ-5D (3D) 
 
Focus: generating 
utilities to reflect 
Migraine severity 
for participants 
most recent attack 
(past 4-weeks) and 
their current 
health state 
outside of an 
attack. 
Tension-related 
aspects of M not 
evaluated. 
 
EQ-5D self-
completed 
retrospectively to 
reflect most recent 
M: completed for 
each level of M 
severity 
experienced (mild, 
mod and/or 
severe) during this 
attack. Also 
completed EQ-5D 
to reflect current 
non-M health 
state. 
 
Stewart et 
al 1999 
[35] 
US and UK 
 
US and UK English 
 
Computer-Assisted 
Telephone Interview 
(CATI) based diagnosis 
of migraine (IHS 
criteria) 
Postal self-completion of MIDAS – population 
based samples of patients with migraine-
headache confirmed with CATI: UK n100  and US 
n97 
 
Baseline and test-retest completion at 18-days 
Range 18-
55yrs 
F 
US 83.5% 
UK 60% 
N/A 
Evaluation of MIDAS 
reliability. 
NR Initial 
development / 
refinement of 
MIDAS and testing 
of reliability 
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Stewart et 
al 1999 
[66] 
 
US 
 
US English 
 
Computer-Assisted 
Telephone Interview 
(CATI) based diagnosis 
of migraine (IHS 
criteria) 
Postal self-completion of MIDAS – population 
based samples of patients with migraine-
headache confirmed with CATI: US n97 and n80 
non-migraine subjects 
 
Baseline and test-retest completion at 21-days 
 
Range 18-
55yrs 
F 
US 83.5% 
 
N/A 
Evaluation of MIDAS 
reliability  
NR Initial reliability 
resting of MIDAS  
Stewart et 
al 2000 
[67] 
 
 
US 
 
US English 
Patients with a 
confirmed diagnosis 
of migraine 
 
Initial migraine status 
determined from IHS 
based CATI algorithm  
 
Migraine status 
confirmed by clinical 
examination at initial 
clinic visit 
 
Population based interview survey 
 
n=144  
(a total of 12967 diary days) 
37.6 (9.3) F 75.7% NA (Treatment As Usual) Interview 
participation rate 
67% 
 
Inadequate diary 
entry 16.5% 
MIDAS 
Stewart et 
al 2003 
[68] 
 
 
US and UK 
English 
 
Total n= 397 
 
59% MIDAS grade III 
or IV 
 
Initial migraine status 
determined from IHS 
based CATI algorithm  
 
Secondary data analysis from three population 
based studies 
Mean NR 
 
62% aged 
25 – 44yrs 
 
(range <25 
to 55+) 
F 78% N/A NR Focus: relationship 
between headache 
features (freq, 
pain intensity, 
quality, assoc 
symptoms) and 
the MIDAS 
 
Telephone 
interview-based 
completion?? 
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Turner-
Bowker et 
al 2003 [7] 
US 
 
US English 
General population  
 
Patient self-report or 
patient-reported 
doctors’ diagnosis of 
migraine 
 
 
Cross-sectional Internet  (AOL) and mail 
population survey 
 
Convenience population sample 
 
Total N=7557 
Migraine n=1478 
 
Range 35–
44 years 
F 53% Not assessed Total 
questionnaire 
response rate 
27.8% 
Internet 
response rate 
unreported 
SF-8 
Vernon & 
Lawson 
2015 [29] 
Canada/UK 
 
Canadian English 
Patients attending a 
chiropractic clinic and 
self-diagnosed with 
primary migraine, 
tension-type or 
cervicogenic 
headache 
 
 
Cross-sectional completion of HADLI 
 
Participants recruited by advertisement/ 
personal solicitation 
 
N 53 
 
37.3 (12) 
yrs. 
F 41 
(77.4%) 
NA NR HADLI 
development 
paper 
Ware et al 
2003 [57] 
US 
 
US English 
General population 
 
At least 1 headache in 
4/52 prior to 
interview (not 
hangover, cold, flu) 
 
Two studies: 
1.National Survey of Headache Impact (NSHI) – 
longitudinal survey (baseline and 3/12) 
Sampling frame: randomly generated list of 
telephone numbers from 48 US states. 
 
Telephone interviews with convenience sample 
of eligible respondents n= 1016 
 
Headache prevalence in 4/52 period= 45.7% 
 
2.On-line community-based survey (platform 
AOL’s Opinion Place): respondents randomly 
  Detail: Ware 2000 *Med 
Care) and Bjorner 2003a [9] 
 HIT (total) 
CAT-HIT  
 
HIT-6-D (‘static’) 
and improved 
version (HIT-6) in 
study 2 
SF-8 
 
Focus: evaluation 
of CAT-based 
estimates vs 
‘static’ scores: 
reliability and 
validity (plus 
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selected and screened for eligibility: n 1103 
included. 
Test-retest at 2-weeks for sub-group (n 540).  
 
 
respondent 
burden) 
 
Xu et al 
2011 
[78]** 
US 
 
US English 
Participants in a 
multi-centre clinical 
trial. 
 
M defined by IHS (+/- 
aura); Between 1 – 6 
moderate to severe 
Migraine  attacks per 
month 
 
Secondary analysis of data from a multi-centre 
(20 sites) double-blind RCT of treatment for 
acute Migraine (Talcagepant). Rx duration was 
for a single Migraine attack of moderate to 
severe intensity. 
 
N 330 
 
All data pooled for EQ-5D analysis. Disutilities 
calculated for selected patients with 
mod/severe Migraine pain at baseline who 
reported pain freedom at 24-hrs (difference in 
EQ-5D scores between time-points calculated) 
 
Mean NR 
 
Range 20-
65 yrs. 
F n 292 
(88.5%) 
 
(Caucasian 
n 259 
(78.5%)) 
. 
 
 
NR EQ-5D (3D) 
 
Completed at 
baseline (whilst 
experiencing a 
mod/severe M and 
prior to dosing) 
and 24-hr post Rx 
within an acute M 
attack. Patients 
also completed 
Pain levels during 
this time (4-grade: 
no/mild/mod/ 
severe). 
 
 
Yang et al 
2010 [56] 
US 
 
US English 
Population based 
survey – self-
completed 
questionnaires 
 
 
CM and EM: 
Categorised into 3-
groups:  
1) CM (=/>15 HDPM) 
= 6.4%;2) EM (<15 
HDPM) = 42.1%; 3) 
Participants in National Survey of Headache 
impact (NSHI) (n= 1096) and the HIT-6 
Validation study (n= 54) 
 
N= 2049 
 
Focus of analysis: reliability and validity of HIT-6 
in patients with varying headache frequency 
days. 
Mean NR 
 
Range 18-
69yrs 
 
56.3% aged 
18-39 
F 75% 
 
 
NA NR HIT-6  
(SF-8) 
 
HIT-6 scores 
calculated across 
the 3 groups:                                             
1) CM = 62.5 (7.8);                             
2) EM  = 60.2 (6.8);                              
3) Non-M 
headache = 49.1 
(8.7) 
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Non-M headache = 
51.5% 
 
Survey included a 
Migraine screener ID 
Migraine criteria – 
p359) and number of 
headache days per 
month (HDPM) 
 
Study 
(Author;yr) 
[ref] 
Countryg 
Languageg 
Population and 
Headache definition 
 
  
Study: design, setting, sample sizeg Mean gage 
(SD; range) 
Gender 
distribution 
(F Female)g 
Treatment descriptionsg % missing 
responses: 
acceptable?g * 
PROM focus; 
Additional info g 
 
Footnote:  
 Missing values: a. At survey level; b. At item level (data quality – frequency with which items were missing (ie. Non-completed) and how did the authors deal with missing values? 
Bagley 2012: HDPM Headache days per month (p410 for detail); IBMS – International Burden of Migraine Study (2009). 
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Appendix 6: Table 5 Content comparison at item level (number of items) of condition-specific measures (n= 17)  
 
 
 
 
 
 
 
PROMa 
 
 
 
 
 
 
Items 
(n) b 
Domains of Health-related Quality of Life (Ferrans et al, 2005 [25])* 
 
 
Response to Treatment 
 
Symptom Status 
 
Functional Status 
General 
Health 
Perception 
Symptoms Physical Social / Role Psychological      
  Social / Role ADL / Work EWB Cognition  Return 
to 
normal  
Confidence / 
Satisfaction 
with Rx 
Side 
effects 
Other 
  General Headache 
Frequency 
Headache 
Intensity 
Pain Physical Limit Prevent Limit Prevent        
                  
Condition-specific (17)                
Migraine impact (5/17)                
FAIM [33] 9 + 5      5    5  4     
HANA [34] 7 1     1  1  3  1     
MIDAS [35] 5 + 2  1* 1*    1 4         
MSQv2.1[36] 14 2     2 1 3 2 3 1      
MSQoL [37] 20      6  10  4       
                  
Headache impact (6/17)                
EUROLIGHT d 
[28] 
103 X X X X X X  X  X X      
HADLI [29] 9 1    1  2 4   1      
HDQ [30] 9    2  1  3 3        
CAT-HIT e 
[3,57] 
54 X   X  X  X  X X      
HIT-6 [31] 6 1   1  1  1  1 1      
SF-36 
Headache 
[32]  
6/36    2 1 2  1         
                  
Response to migraine-specific treatment (6/17)              
Static CORS 
Comp CORS 
[38] 
24 
 
8 
9 
 
4 
  5 
 
   2  3 1  1 
 
1 
3 
 
3 
  
M-ACT [39] 27 
4 
            20 
2 
7 
2 
  
M-TAQ [40] 9 1 1       1    1 1  4 
M-TOQ15 
M-TOQ-5 
[41] 
15 
5 
1  1 2 
1 
   2 
1 
 1   1 4 
2 
3 
1 
 
MTSM [42]  45  1   3    1      3   
PPMQ-R [43] 19  
10 
3 
8 
  6  2  2  1 
1 
 
1 
2 (cost)  3   
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Footnote: 
*Ferrans et al (2005) revision to the Wilson and Cleary Model of Health Related Quality of Life (HRQOL)[25]: The model describes five levels of patient outcomes from biological and psychological variables through to 
overall quality of life (subjective well-being assessed by an individuals perceived level of happiness or satisfaction with life), and includes symptoms (for example, physical, emotional, cognitive symptoms perceived by the 
patient), functional status (for example, physical, social, role and psychological function) and general health perceptions (a subjective rating incorporating all of the preceding health concepts). Additionally, characteristics 
of the individual (such as values and preferences) and those of the environment (such as social, economic and psychological support) are considered. 
 
a PROM content; b Number of items per PROM 
Migraine-impact: 
a FAIM – Functional Assessment in Migraine: 9 items across three domains. 1) Attention/Thought (5 items); 2) Perception (4 items); 3) Activity and Participation (5 items) 
HANA - Headache Needs Assessment: 7 items to reflect migraine frequency and bothersomeness. 1 item in each of following area: Anxiety/worry; depression/discouragement; self-control; energy; function/work; 
family/social activities; overall impact of migraines. 
MIDAS - Migraine Disability Assessment Score: 3 domains (5 scored items): Missed days/ reduced productivity at paid work (2 items); Missed days/ reduced productivity at household work (2 items); Missed non-work 
activities (1 items) 
MSQv2.1 - Migraine-Specific Quality of Life Questionnaire version 2.1: 3 domains (14 items): 1) Role function – Restrictive (RR)(7 items): social – family/friends; leisure (2); work/ADL (3); cognition (1); symptoms: fatigue (1); 
2)  Role function – Preventive (RP)(4 items): symptoms: fatigue (1); work /ADL (2); social (1); 3) Emotional function (EF)(3 items): frustration (1); feeling a burden (1); letting others down (1). 
MSQOL - Migraine-Specific Quality of life: 3 domains (20 items): 1) Avoidance behaviours (10); 2) Social relations (6); 3) Feelings (4). 
 
Headache impact: 
EUROQLIGHT: 6 sections (103 items): 1) Biographical (age, gender, language and employment); 2) Screening questions for headache; 3) Diagnostic questions; 4) Questions about any headache experienced ‘yesterday’ 
(point prevalence); 5) Use of healthcare resources (medicines, investigations, consultations, etc.); 6) Impact of headache on work, family life and social activities: includes items taken from the WHOQOL (8-items), the 
HALT-index and HADS. d EUROLIGHT – number of items per domain not clear (denoted by X). 
HADLI - Headache Activities of Daily Living Index: 1 domain (9 items): Personal care, Lifting, Reading (including computers), Sleeping (over last week), Exercising (over last week), Social activities, Work, Driving or travelling, 
Recreation. 
HDQ – Headache Disability Questionnaire: 3 domains (9 items): 1) Pain (2 items): usual pain intensity; when pain is severe; 2) Activity Limitation (4 items): Decreased efficiency in non-work activities; Decreased ability to 
work/study; Decreased efficiency in housework or chores; Proportion of times when work is missed; 3) Activity Prevention (3 items): Number of days where chores prevented;  
Number of days non-work activities prevented; Number of days in last month when had to lie down for >1 hour. 
HIT (CAT-HIT) - Headache Impact Test: One domain ‘Headache Impact’: 54-item ‘item bank’. Items cover a wide spectrum of headache impact, including minor headache. Items cover of pain, role and social functioning, 
energy/fatigue, cognitive function, and mental health. 
e CAT-HIT: Number of completed items is individualised and determined by ‘stopping rule’: mean number 6/54 items (denoted by X) 
HIT-6 – Headache Impact Test -item (static): 6 domains (6 items): 1) Headache pain severity(1); 2) Social functioning - usual daily activities(1); 3) Role functioning (how often do you wish you could lie down?) (1); 4) 
Vitality(1); 5) Cognitive functioning(1); 6) Psychological distress(1). 
SF-36 Headache - Inserts ‘including your headaches’ to 6/36 items: physical functioning (item 3); role limitation - physical (item 4); social functioning (items 6 and 10); bodily pain (items 7 and 8) 
 
Response to migraine-specific treatment: 
CORS - Completeness of Response to Migraine Therapy Survey: Two modules:1.‘Static CORS’ – 5 domains (24 items): 24-items address: Symptoms, Emotional well-being, Cognition, ADL, Function, Confidence in current 
medical. 2. ‘Comparative CORS (8 domains (8 items)): Completeness of Relief (1), Speed of Relief (1), Persistence of Relief (1), Return to Normal Function (1), Fatigue (1) 
Confidence in Treatment (2), Overall Satisfaction (1) – most satisfied. 
M-ACT - Migraine – Assessment of Current Therapy: 4 domains (27 long-form/ 4 short): Headache impact (11/1); Global assessment of relief (9/1); Consistency of response (3/1); Emotional response (4/1). 
M-TAQ - Migraine Therapy Assessment Questionnaire: 9 items - Migraine control, frequency of attacks, knowledge and behavioural barriers, economic burden, treatment satisfaction. 
M-TOQ - Migraine-Treatment Optimization Questionnaire M-TOQ: 15- and 5-item versions: 5 domains (15/5 items): Functioning (3/1), Rapid relief of headache (3/1), Consistency of response (3/1), Prevention of recurrence 
(3/1), Side effects (3/1). 
MTSM - Migraine Treatment Satisfaction Measure: 4-part assessment: 1) Expectations of Treatment for Migraine (TE-M; 9 items); 2) Importance Ranking for Migraine Treatment (IR-M; 9 items); 3) Outcomes of Treatment 
for Migraine (TO-M; 9-items); 4) Satisfaction with Migraine Treatment (PST-M; 9-items). Considered across 9 attributes (‘items’) associated with migraine relief: Pain relief; Speed of relief; Freedom from pain; Additional 
symptoms; Confidence in treatment; Disruption in life; Dosing; Freedom from relapse; Ease of use 
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PPMQ-R - Patient Perception of Migraine Questionnaire -Revised: Core: 4 domains (19 items): Efficacy: satisfaction with treatment efficacy (11); Function: ability to perform usual activities (4); Ease of Use (2); Cost (2) (may 
be removed where ‘cost’ is not a consideration). Additional fifth domain (10 items): ‘Bothersomeness’ or ‘Tolerability’ - related to side effects (10). 3 global items: Overall  satisfaction with medication effectiveness; Side 
effects; General treatment. 
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Appendix 7: Table 6: Methodological quality (COSMINa) of each study (n=46) per PROM (n=23) and investigated measurement property. 
PROMb 
Study (n) 
Country 
(language) 
Headache 
definitionc 
 (n) Reliability Validity Responsiveness Interpretability 
Internal 
consistency 
Reliability Measurement 
error 
Content 
validity 
Structural 
validity 
Hypothesis 
testing 
Known-
groups 
validity 
Responsiveness 
(COSMIN) 
Responsiveness 
- other 
 
Condition-specific (17)             
Migraine-impact (5/17)             
FAIM (1)              
Pathak et al 
2005 [33] 
US English 
German 
M 69 
83 
Good  
 
  Fair Good  
 
Good  
 
    
              
HANA (1)              
Cramer et al 
2000 [34] 
US English M  Poor 
 
Poor 
 
 Poor Poor 
 
Poor  
 
Poor 
 
   
              
MIDAS (12)              
Stewart et al 
1999a [35] 
US and UK 
English 
M (IHS) US 97 
UK 100 
Poor 
 
Poor 
 
        
Stewart 
1999b [66] 
US English M (IHS) 97 Poor 
 
Poor 
 
        
Stewart et al 
2000 [67] 
US English M (IHS) 144      Fair 
 
    
Stewart et al 
2003 [68] 
US and UK 
English 
M (IHS) 397      Poor     
Bigal et al 
2003 [69] 
US English CM 182       Fair 
 
   
Dodick et al 
2007 [61] 
US English CM (ICHD-II) 328        Fair   
Martin et al 
2008 [65] 
US English CH – 
TT/M/mixed 
124      Fair 
 
    
Lipton et al  
2009 [41] 
Multiple M (IHS) 253 Poor 
 
    Fair 
 
    
Sauro et al  
2010 [70] 
Canadian 
English 
CH (IHS) 798      Fair 
 
Fair 
 
   
Blumenfeld 
et al 2010 
[71] 
Multiple CM; EM 8726       Fair 
 
   
Yang et al 
2010 [56] 
US English CM; EM >600      Good 
 
Good 
 
   
Bagley et al  
2012 [54] 
Multiple CM; EM 8726 
total 
     Fair 
 
    
Stafford et al 
2012 [72] 
UK English M (IHS) 105      Fair 
 
    
              
MSQ v2.1 (9)              
Martin et al  
2000 [36] 
US English M (IHS) / 
EM 
267 Good 
 
Good 
 
 Fair  Excellent 
 
Excellent 
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Revicki et al  
2006 [43] 
US English EM (IHS 1.1, 
1.2) 
200      Good 
 
    
Dodick et al 
2007 [61] 
US English CM (ICHD-II) 328        Fair  Poor 
Cole et al 
2007 [51] 
US English EM (IHS)  916 Excellent 
 
   Excellent 
 
Fair 
 
    
Cole et al 
2009 [60] 
 
US English EM           Fair 
 
Blumenfeld 
et al 2010 
[71] 
US English  CM and EM        Fair 
 
   
Bagley et al 
2012 [54] 
US English CM; EM 8726 
total 
Fair 
 
    Fair 
 
Fair 
 
   
Gillard et al  
2012 [73] 
Multiple 
 
CM; EM 8726 
 
      Fair 
 
   
Rendas-
Baum et al  
2013 [12] 
US English CM (ICHD-II) 1376 Good 
 
Good 
 
  Good 
 
Good 
 
Good 
 
 SRM  
Rendas-
Baum et al 
2014 [53] 
US English CM (ICHD-II) 1376      Good 
 
    
Lipton et al 
2016 [59] 
US English CM (ICHD-II) 1236         % exceeding 
MIC or MID 
 
              
MSQoL (3)              
McKenna et 
al 1998 [37] 
UK English M (IHS)  Poor 
 
Fair 
 
 Excellent  Poor 
 
Fair 
 
   
Patrick et al 
2000 [52] 
US English M 1376 Fair 
 
  Fair Good 
 
 Fair 
 
 ES; SRM Poor 
 
Lipton et al 
2009 [41] 
Multiple M (IHS) 
(EM?) 
253 Poor 
 
    Fair 
 
    
              
Headache-impact (6/17)            
EUROLIGHT (1)             
Andree et al  
2010 [28] 
Multiple  
UK English 
Headache – 
all types 
426 
131 
Poor 
 
Poor  
 
 Fair  Poor 
 
Poor 
 
   
              
HADLI (1)              
Vernon et al  
2015 [29] 
Canadian 
English 
Self-
diagnosed 
headache: 
M, TT, CG 
53 Fair 
 
  Poor Fair 
 
     
              
HDQ (1)              
Niere & Quin 
2009 [30] 
Australian M (IHSD); 
Mixed: TT, 
CG, ‘other’ 
111 Fair 
 
  Poor Fair 
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HIT  (3)              
Bjorner et al 
2003a [3]      
US English H (C or E) 1016    Fair Excellent 
 
     
Ware et al 
2003 [57]  
US English H 1.1016 
2.1103 
 
 Fair 
 
 Fair  Good 
 
Good 
 
Poor   
Kosinski et al 
2003a [31] 
US English H 1103  Fair 
 
 Fair  Fair 
 
Fair 
 
   
              
HIT-6 (12)              
Kosinski et al 
2003a [31] 
US English H 1103 Fair 
 
Fair 
 
 Fair  Fair 
 
Fair 
 
Fair    
Ware et al 
2003 [57] 
US English H 1.1016 
2.1103 
 
 Fair 
 
 Fair  Good 
 
Good 
 
Poor   
Kawata et al  
2005 [55] 
US English H 309 Fair 
 
   Fair 
 
Fair 
  
    
Coeytaux et 
al 2006 [58] 
US English CDH  71          Fair 
 
Lipton et al 
2009 [41] 
Multiple M (IHS) 
(EM?) 
253 Poor 
 
    Fair 
 
    
Sauro et al  
2010 [70] 
Canadian 
English 
CH (IHS) 798      Fair 
 
Fair 
 
   
Yang et al  
2010 [56] 
US English CM; EM >600 Good 
 
Fair 
 
   Good+ Good 
 
   
Gillard et al  
2012 [73] 
Multiple M (ICHD): 
CM and EM 
9048 
 
      Fair 
 
   
Bagley et al  
2012 [54] 
US English CM; EM 8726 
total 
     Fair 
 
    
Magnusson 
et al 2012 
[32] 
US English CM (+/- 
MOU) 
159      Poor 
 
    
Rendas-
Baum et al  
2013 [12] 
US English CM (ICHD-II) 1376      Good 
 
    
Rendas-
Baum et al 
2014 [53] 
US English CM (ICHD-II) 1376 Good Good 
 
  Good Good Good 
 
 SRM  
Lipton et al 
2016 [59] 
US English CM (ICHD-II) 1236         % exceeding 
MIC or MID 
 
              
SF-36 ‘Headache-specific’ (1)            
Magnusson 
et al 2012 
[32] 
US English CM  
 
159    Poor / 
nil 
 Fair 
 
    
              
Response to migraine-specific treatment (6/17)           
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CORS (1)              
Coon et al  
2012 [38] 
US English M (IHS) 916 Fair 
 
  Good Fair 
 
Fair 
 
 Fair 
 
  
              
M-ACT (2)              
Dowson et al  
2004 [39] 
Multiple M (IHS) 185  Fair 
 
 Poor  Poor 
 
    
Kilinster et al 
2006 [74] 
Multiple M (IHS) 185  Fair 
 
   Poor 
 
    
              
M-TAQ (1)              
Chatterton 
et al 2002 
[40] 
US English M (IHS) 243  Fair  
 
 Fair  Fair 
 
    
              
M-TOQ 19/15/5 (1)             
Lipton et al 
2009 [41] 
Multiple M (IHS) 
(EM?) 
253 Fair 
 
Fair 
 
 Fair Fair 
 
Fair 
 
    
              
MTSM (2)              
Patrick et al  
2003 [42] 
US English M 29 Poor   Good  Fair Fair    
Martin et al  
2008 [65] 
US English CH – 
TT/M/mixed 
124 Fair 
 
  Poor Fair 
 
Good 
 
Good 
 
   
              
PPMQ-R (2)              
Revicki et al  
2006 [43] 
US English EM (IHS 1.1, 
1.2) 
200 Excellent 
 
Fair 
 
 Excellent Excellent 
 
Excellent 
 
Good 
 
 ES Fair 
 
Kimel et al 
2008 [75] 
US English M (IHS) 1304 Excellent 
 
   Good 
 
Good 
 
Good 
 
   
              
Generic measures (6)             
Profile measures (3/6)             
SF-36 (5)              
Patrick et al 
2000 [52] 
US English M 1376         ES, SRM  
Martin et al 
2000 [36] 
US English M (IHS) / 
EM 
267      Good  
 
    
Davis et al 
2002 [76] 
Multiple M (IHS) 793  
 
    Poor  
 
    
Kawata et al 
2005 [55] 
US English H 309      Fair 
 
    
Martin et al  
2008 [65] 
US English CH – 
TT/M/mixed 
124      Fair 
 
    
              
SF-12 (1)              
Lipton et al 
2003 [75] 
US and UK 
English 
M (IHS) M 399       Fair 
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Control 
379 
              
SF-8 (4)              
Kosinski et al 
2003a [31] 
US English M (self-
report) 
1103      Fair 
 
    
Ware et al 
2003 [57] 
US English H 1.1016 
2.1103 
 
     Good 
 
    
Turner-
Bowker et al  
2003 [7] 
US English M (self-
report) 
465      Good 
 
Good 
 
   
Yang et al  
2010 [56] 
US English CM; EM >600      Good 
 
Good 
 
   
              
Utility measures (3/6)             
EuroQoL EQ-5D-3L (3)             
Xu et al  
2011 [78]** 
US and UK 
English 
M (HIS) 330       Poor 
 
    
Gillard et al  
2012 [73] 
Multiple M (ICHD): 
CM and EM 
9715 
CM 
555 
EM 
9160 
      Fair 
 
   
Stafford et al  
2012 [72] * 
Uk English M (IHS) 105      Fair 
 
Fair 
 
   
              
HUI-3 (1)              
Brown et al  
2008 [79] 
US English EM 150       Poor 
 
   
              
QWB and QWB-SA (1)             
Sieber et al  
2000 [64] 
US English M 89  Poor 
 
    Fair 
 
   
 
Footnote: 
a COSMIN – Consensus on Standards for Measurement Instruments. Four-grade rating for study methodological quality: Excellent, Good, Fair Poor. [20,21]    
b PROM acronyms (detailed in text and Tables 1 and 2) 
c Headache definition: H – Headache (general); CH – Chronic Headache; TT – Tension Type; CG – Cervico Genic; CDH – Chronic Daily Headache; M – Migraine; EM – Episodic M; CM – Chronic M; IHS – International Headache 
Society – headache classification system (https://www.ichd-3.org/); ICHD – International Classification of Headache Disability (https://www.ichd-3.org/). 
*Focus of paper: generating utilities to reflect Migraine severity; **Focus of paper: calculating disutilities.  
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Table 1: Data synthesis, levels of evidence and overall quality of reviewed PROMs (n=23)a    
PROMb / 
Study 
Number of 
evaluations 
Reliability Validity Construct Validity  Responsiveness Interpretation 
Internal 
consistency 
Temporal 
stability 
Measurement 
error 
Content 
validity 
Structural 
validity 
Hypothesis 
testing 
Known-
groups  
Responsiveness  
Condition-specific (17)         
Migraine- impact (5/17)         
FAIM [33] 1 + 
Moderate 
  ? 
Limited 
+ 
Moderate 
+ 
Moderate 
   
HANA [34] 1 + 
Unknown 
+ 
Unknown 
 ? 
Unknown 
? 
Unknown 
? 
Unknown 
? 
Unknown 
ES only  
MIDAS [35] 13 + 
Unknown 
+ 
Unknown 
   + 
Moderate 
+ 
Moderate 
  
MSQ v2.1 
[36] 
11 + 
Strong 
+/- 
Conflicting 
 + 
Limited 
+ 
Strong 
+ 
Moderate 
+ 
Moderate 
 + 
Limited 
MSQoL [37] 3 + 
Limited 
  + 
Strong 
+ 
Moderate 
? 
Unknown 
? 
Unknown 
 ? 
Unknown 
           
Headache-impact (6/11)         
EUROLIGHT 
[28] 
1 ? 
Unknown 
? 
Unknown 
 ? 
Limited 
 ? 
Unknown 
? 
Unknown 
  
HADLI [29] 1 + 
Limited 
  ? 
Unknown 
+ 
Limited 
    
HDQ [30] 1 + 
Limited 
  ? 
Unknown 
+ 
Limited 
    
HIT [3,57] 3  + 
Moderate 
 + 
Limited 
+ 
Moderate 
+ 
Moderate 
+ 
Moderate 
  
HIT-6 [31] 13 + 
Strong 
+ 
Moderate 
 + 
Limited 
+ 
Moderate 
+ 
Strong 
+ 
Strong 
 + 
Limited 
SF-36 
‘Headache’ 
Modification 
[32] 
1    ? 
Unknown 
 ? 
Unknown 
   
           
Response to migraine-specific treatment (6/17)        
CORS [38] 1 + 
Limited 
  + 
Moderate 
+ 
Limited 
? 
Limited 
 + 
Limited 
 
M-ACT [39] 2  + 
Moderate 
 ? 
Unknown 
 ? 
Unknown 
   
M-TAQ [40] 1  + 
Limited 
 + 
Limited 
 + 
Limited 
   
M-TOQ [41] 1 + 
Limited 
+ 
Limited 
 + 
Limited 
+ 
Limited 
+ 
Limited 
   
MTSM[42] 2 + 
Limited 
  + 
Moderate 
+ 
Limited 
+ 
Moderate 
+ 
Moderate 
  
PPMQ-R [43] 2 + 
Strong 
+ 
Limited 
 + 
Strong 
+ 
Strong 
+ 
Strong 
+ 
Strong 
 + 
Limited 
           
Generic measures (6)         
Profile measures (3/6)         
SF-36 [44] 5      + 
Moderate 
   
SF-12 [45] 1       + 
Limited 
  
SF-8 [46] 4      + 
Moderate 
+ 
Moderate 
  
         
Utility measures (3/6)         
EuroQoL  
EQ-5D-3L 
[47] 
 
3      + 
Limited 
+ 
Limited 
  
HUI-3 [48] 
 
1       ? 
Unknown 
  
QWB / QWB-
SA [49,50] 
1  +/- 
Conflicting 
    ? 
Unknown 
  
           
 
Footnote: a Data synthesis: The data were qualitatively synthesized to determine the overall quality of measurement properties and acceptability of each reviewed PROM. The 
synthesis took the following factors into account: 1) methodological quality of the reviewed studies (COSMIN scores); 2) the number of studies reporting evidence of 
measurement properties per PROM; 3) the results for each measurement property for each PROM; and 4) the consistency of results between reviewed studies.  
The data synthesis score has two elements [19,27]:  
First, the overall quality of a measurement property was reported as: adequate (+), not adequate (-), conflicting (+/-), or unclear/indeterminate (?) (Table 1 for detail). 
Second, levels of evidence for the overall quality of each measurement property were further defined to indicate: 
‘strong’ – consistent findings in multiple studies of good methodological quality OR in one study of excellent quality;  
‘moderate’ – consistent findings in multiple studies of fair methodological quality OR in one study of good methodological quality;  
‘limited’ – one study of fair methodological quality;  
‘conflicting’ – conflicting findings; or 
‘unknown’ evidence – only studies of poor methodological quality  
Where the data entry box is left blank, this signifies no available evidence. 
 
 
Figure 1: Review of measures used with people with headache – PRISMA flow diagram for article selection (search conducted 1980 to December 2016) 
 
 
Records identified through database searches –  Medline and EMBASE (OVID) 
Searched 1980 – December 2016 
Construct search: EMBASE (n= 10296); Medline (n= 1405) 
Named measure search: EMBASE (n=1760); Medline (n= 1243) 
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